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CHAPTER I 
GENERAL INTRODUCTION 
1. Prognostic factors in urologica! oncology 
During the last decades many efforts have been made to define prognostic factors 
in oncological urology, attempting to keep pace with the individual need of new 
therapeutic options for patients with cancer. Prognostic parameters related to the patient 
and his cancer may influence the choice of treatment. With these prognostic factors, 
subsets of patients can be defined that correspond to the characteristics of their disease. 
Questions as to the risk for recurrence or the chance for survival, are of 
importance in daily clinical practice. Each physician must be aware of the natural history 
of the tumor and its response to treatment, in order to be able to inform the patient. We 
are still unable to predict the exact course of the disease for the individual patient by 
using prognostic factor techniques. We have learned from our statisticians that we can 
only make statements about the probability of recurrence and survival. With these 
restrictions in mind, research on prognostic factors remains of great importance for the 
analysis in clinical oncological studies. 
First of all, we have to clarify the definitions of prognosis and of a prognostic 
factor in order to be able to use these terms (Fletcher, 1988). Prognosis is a prediction 
of the future course of the disease, following its onset. Prognosis depends on the response 
of the patient to the cancer, the potentiality of the neoplasm, and the kind of treatment 
received. Prognostic factors are the conditions which, when present in persons already 
known to have the disease, are associated with the outcome of the disease. Prognostic 
factors can be subdivided by a natural classification which includes (1) host factors, (2) 
tumor characteristics, and (3) the effects of the tumor on the host (Byar, 1986). Examples 
of the first category are age, sex and the blood group. Examples of the second are the 
histological and morphometric characteristics, while performance status, laboratory results 
and metastasis patterns are examples of the last category. 
Knowledge of prognostic factors may assist in the design of future trials in several 
ways. Prognostic factor studies permit us to focus on therapeutic regimens in appropriate 
subsets of patients and should lead to an improvement in the basic understanding of 
tumor biology. For some planned treatment comparisons, it may be desirable to stratify 
the patients according to prognostic groups. In this way, patients can be divided into 
good, intermediate and poor risk groups according to certain prognostic factors. Risk 
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group membership can be used as an indication of the prognostic variables for each 
member, and may provide information for the individual patient. It will also make these 
patients accessible for treatment comparison and can therefore be used for a stratified 
randomization in future studies. A 'prognostic stratification' should be at the basis of 
most choices of therapy. 
Mainly because the clinician is interested in answers about the probable course 
of the disease, they are interested in the results of studies of prognostic factors. A 
clinician arrives at a prognosis for a new patient by means of recalling the results in a 
group of previously treated patients with the same characteristics. However, this 
resemblance is merely an incomplete abstraction of the results from prognostic analyses. 
Prognostic factor recognition is an important step towards the notion that treatment in 
oncological patients must have an individualized basis, mainly because of the 
heterogeneity of the characteristics of the patient and his tumor. 
New treatment modalities may improve the survival of patients. Almost every new 
trial in which certain subsets of patients with cancer are treated, is nowadays 
accompanied by an analysis of its prognostic factors. The results will help in the 
evaluation of the trial and will be beneficial for the development of future studies. 
For the urologist, patients with cancer constitute a substantial part of his practice. 
Also for this purpose, it is essential to develop a classification of cancer based upon 
anatomic and histological considerations. This is the cornerstone of cancer decision-
making as a multidisciplinary process. Anatomical staging gives information about the 
extent of the disease. This is done by the Tumor, Nodes and Metastases (TNM) 
classification. The International Union Against Cancer (UICC) is one of the most 
important organisms in the field of the classification of malignancies (UICC, 1987). Its 
objectives will help the clinician to plan treatment, assist in the evaluation of the 
treatment results for clinical research, and facilitate the exchange of information. 
Statistical considerations 
The role of the statistician must be clearly defined. The statistical groundwork of 
the prognostic factor analysis in clinical oncology must be performed by professional 
statisticians. An independent specialist in this field should, in principle, guarantee the 
objectivity of the outcome of our clinical studies. Physicians must know and be able to 
11 
interpret these results and use them to inform their patients. 
The results of a prognostic factor analysis must be interpreted with caution, 
because they depend on several constraints by which every study is influenced. Usually 
a prognostic factor analysis is performed in a retrospective way. The results will be 
influenced by the disadvantages of this method. For example, missing data and drop-outs 
for unknown reasons will influence especially the results of a multivariate analysis. 
Missing data require a listwise non-random selection of patients for statistical analysis 
with possibly biased results. However, advantages of a retrospective study are that the 
results can be obtained within a relatively short period of time. These results may than 
be helpful in designing future studies. 
Prognostic factor analysis can also be performed as a side-study of the cancer 
treatment protocols. These trials have the advantage of a good documentation. The 
results from the prognostic factor analysis of these studies are a function of the study 
design. First of all, the results of the prognostic factor analysis may be influenced by the 
accrual periods of patients. In this way different groups of patients with the same tumor 
characteristics, but recruited at different times, may possess different prognostic values. 
For example the inclusion of patients in a study may depend on the current opinion of 
the physician on a particular therapy. The results will also be influenced by the inclusion 
criteria of the study. It is important to take into account all the inclusion criteria before 
drawing any conclusion. Another important feature is the number of characteristics which 
will be included in the prognostic factor analysis. The prognostic value of a certain 
characteristic, may be different when it is included in another set of factors. The number 
of treatment arms of the trial is also of importance. When the prognostic factor analysis 
is restricted to treatment, still slight differences may have a great impact on the outcome 
of the prognostic analysis. The number of physicians and centres (in case of a multicenter 
study) from which the patients are recruited is also important for the study design. Unless 
an adequate protocol design exists, differences between different centres may occur and 
will influence the outcome of the results. From all these statements, it must be concluded 
that it is hazardous to group the results of different studies for one prognostic factor 
analysis. The advantage of a large number of patients decreases by the diminishing 
reproducibility of the results. From a statistical point of view it is better to have results 
from an independent prognostic factor analysis. 
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The results of the prognostic factor analysis will also be influenced by the 
technical-statistical procedures. The choice of statistical tests and the development of 
statistical analytic models (proportional hazard model versus logrank or Wilcoxon model 
free) will influence the results (Cox, 1972). The variables may be analyzed simultaneously 
to detect the functional relation of each factor. Some relation between prognostic factors 
is always present, and must be taken into account in order to arrive at valid conclusions. 
An explanation of more technical aspects is however beyond the scope of this thesis. 
Certain standard procedures are available to diminish the subjectivity of choice. 
In this chapter, we want to summarize the most relevant prognostic factors in the 
four most prevalent urological tumors, namely the renal cell carcinoma, superficial 
bladder tumors, disseminated prostatic carcinoma and disseminated germ-cell tumors. 
This will be the basis for our investigations which will be presented in the following 
chapters of this thesis. 
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2. Prognostic factors in germ-cell tumors 
2.1. Introduction 
In contrast with the other urological neoplasms the prognosis of germ-cell tumors 
is good, even in an advanced stage. The survival for the several stages ranges from 70 to 
95% (Zwaveling, 1985). The improvement in survival is mainly due to the development 
of cis-platinum based combination chemotherapy in 1976 for disseminated germ-cell 
tumors (Einhorn, 1977). However, this progress should not lead to resignation in the 
management of these patients. Several studies have been done to get a better insight in 
the timing and extend of the different phases of treatment (Donohue, 1979). As a result, 
it is now generally accepted that the treatment strategy of advanced stages of 
disseminated germ-cell tumors should be primary chemotherapy and not primary 
debulking surgery (Donohue, 1980, Einhorn, 1981, Donohue, 1984, Stoter, 1984). 
The good prognosis of the different stages of the disease has changed the interest 
of treatment towards the reduction of side-effects from both chemotherapy and surgery 
without affecting the good survival rate. On the basis of prognostic factors patients are 
divided in different risk groups (good, intermediate, and poor prognosis) and the 
treatment can be adapted accordingly. The individualization of treatment might thus lead 
to less cycles or a lower dose of chemotherapy or a less agressive or even abandoned 
surgery for patients with good prognostic factors and more agressive therapy for those 
at high risk (Einhorn, 1987, Williams, 1987, Donohue, 1988, Lotherington Ovist, 1991). 
It is important, however, for trial comparison afterwards, to use uniform entry criteria 
(Bajorin, 1988, Bosl, 1991). Studies on prognostic factors are thus important in order to 
establish the least aggressive treatment in patients with a good prognosis and to improve 
survival in patients at risk. 
In this chapter we want to summarize the most relevant prognostic factors known 
in literature and used for treatment decisions. 
2.2 Pathologic prognostic parameters 
The histology of the primary germ-cell tumor obtained after orchiectomy has been 
used as a classification with prognostic implications (Dixon, 1953). Nowadays the two 
mostly applied classifications are the British by Collins and Pugh and the WHO by 
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Mostofi and Sobin (Collins, 1976, Mostofi, 1977). Table 1 shows these two classification 
models. 
Table 1 : Classifications of histology in germ-cell tumors 
Collins and Pugh (1976) Mostofi and Sobin (1977) 
Seminoma 
Spermatocystic 
Teratoma, differentiated (TD) 
Malignant teratoma, intermediate 
(MT!) 
Malignant teratoma, 
undifferentiate (MTU) 
Malignant teratoma, trophoblastic 
(MTT) 
Yolk sac tumor 
Seminoma 
Spermatocystic 
Teratoma Mature 
Immature 
With malignant transformation 
Embryonal carcinoma and teratoma 
Embryonal carcinoma (adult type) 
Choriocarcinoma with or without 
embryonal carcinoma and/or teratoma 
Yolk sac tumor (endodermal sinus tumor) 
Modifications on these classifications have been proposed but were not included 
mainly because of the risk of confusion and the need for comparable groups in 
international literature (Mostofi, 1990). The most important consequence for therapy 
which is derived from these histologic classification models is the distinction between 
semonima and поп-seminoma. Treatment for early stages differs substantially. In the 
advanced stage all germ-cell tumors are treated by chemotherapy in the first place, as 
previously mentioned. 
Within these classification models there are some histologic patterns which have 
prognostic importance. Vascular and/or lymphatic invasion, the presence of yolk-sac 
elements, and the presence of undifferentiated tumor, independently were related to a 
higher relapse rate, especially, stage I non-seminomatous germ-cell tumors (Javadpour, 
1986, Freedman, 1987, McLeod, 1991). Patients with metastases of a primary tumor 
containing teratomatous elements have a worse prognosis and this may have implications 
for treatment decisions (Javadpour, 1986, Donohue, 1987, Lotherington Qvist, 1991). 
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23 Radiographic prognostic parameten 
After orchiectomy accurate identification of the extent of the disease in the 
individual patient is mandatory for an appropriate prognostic classification and 
consequently for the choice of treatment. The generally accepted staging system is the 
Royal Marsden classification (Peckham, 1979) (Table 2). 
Table 2 : Royal Marsden Classification 
STAGE I: Tumor limited to the testis. 
STAGE II: Infradiaphragmatic nodal disease 
(The diameters relate to cross-sectional measurements, not vertical.) 
IIA: Retroperitoneal metastases < 2 cm diameter 
IIB: „ „ 2-S cm „ 
IIC: „ „ 5-10 cm „ 
HD: „ „ >10 cm „ 
STAGE III: Supradiaphragmatic nodal disease 
STAGE IV: Haematogenic metastases (liver, lung, brain, etc) 
Improvements of imaging technics, especially CT-scanning, have been made and 
increased the accuracy of this staging of especially retroperitoneal lymphnode metastases 
(Husband, 1985, Kennedy, 1985). The accuracy of these imaging techniques is however 
not higher than 70%. The evaluation of retroperitoneal mass before and after 
chemotherapy is also essential in the decision of adjuvant surgical treatment (Donohue, 
1982, Oliver, 1983, Stomper, 1985, Donohue, 1987). CT-scanning is usefull in this 
prospect because of its correlation with postchemotherapeutic histologic surgical outcome 
(Husband, 1982, Stomper, 1985). The usefulness of the magnetic resonance impedance 
(MRI) concerning adequate detection of primary tumor location and the follow-up, still 
has to be established. 
2.4 Biochemical prognostic parameters 
The identification of the tumormarkers alpha-fetoprotein (a-FP), beta-subunit 
human chorionic gonadotropin (ß-HCG) and lactic dehydrogenase (LDH) are useful in 
the determination of prognosis in germinal tumors (Lange, 1977, Scardino, 1977, 
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Newlands, 1983, Droz, 1988). They are used to establish the diagnosis, to monitor 
response to chemotherapy and to detect recurrent disease (Lange, 1977). The presence 
in the serum of these tumormarkers is related to the histological pattern of the tumor 
and therefore have a prognostic impact. Quantitative measurements also show a 
correlation with survival. Therefore these tumormarkers, wether or not in combination 
with other features, can be used in the determination of risk groups and the development 
of classification models (MRCWP on Testicular Tumours, 1985, Birch, 1986, Bajorin, 
1988, Droz, 1988, Bosl, 1991). 
Table 3 contains a summery of investigations on prognostic factors in disseminated 
germ-cell tumors. 
Table 3: + = significant correlation, - = no significant correlation 
trophoblastic 
components 
Û-HCG4 
«-FP 
LDH 
tumor size 
abdominal 
metastases 
lung 
métastasas 
Jiver,bra1n,bone 
metastases 
Bosl 
'83 
n=171 
-
+ 
-
+ 
+ 
MRCWP 
'85 
n=45a 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Birch 
'86 
n=180 
-
+ 
+ 
+ 
+ 
+ 
Stoter 
'87 
n=163 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Droz 
'88 
n=84 
-
+ 
+ 
+ 
-
Mead 
'92 
n=79S 
+ 
+ 
+ 
+ 
+ 
+ 
It is essential in the management of germ-cell tumors to use a combination of 
histological, radiographic and biochemical parameters in order to make a treatment 
decision. Treatment often includes chemotherapy and surgery and this intensive therapy 
has attributed to the good prognosis of this tumor. Recently classification models of 
prognostic factors have been developed. The European Organization for Research and 
Treatment of Cancer (EORTC) classification of prognostic factors and the Indiana 
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classification of extend of disease attempt to categorise patients in order to predict the 
results of treatment (Birch, 1986, Stoter, 1987). In both cases risk groups are defined and 
the treatment can be adapted accordingly. These models are shown in table 4 and 5. 
Table 4: EORTC CLASSIFICATION MODEL 
Good prognosis (all of the following) 
- Lymph node metastases < 5cm in diameter 
- Lung metastases < 4 in number, < 3 cm in diameter 
- beta-HCG < 1000 ng/ml (< 5000 IU/I) 
- alpha-FP < 1000 ng/ml 
Intermediate prognosis (any of the following) 
- Lymph node metastases 5-10 cm in diameter 
- Lung metastases > 4 in number 
- Lung metastases > 3 cm in diameter 
- beta-HCG < 1000-9999 ng/ml (5000-49999 IU/I) 
- alpha-FP > 1000ng/ml 
Poor prognosis (any of the following) 
- Lymph node metastases > 10 cm in diameter 
- beta-HCG > 10000 ng/ml (>50000 IU/I) 
- Extragonadal germ cell tumors 
- Metastatic sites other than lymph nodes and lung 
(liver, bone, brain, etc) 
Table 5. Indiana classification model 
Minimal 
1 Elevated beta-HCG and/or alpha-FP only 
2 Cervical nodes (non-palpable retroperitoneal nodes) 
3 Unresectable, but nonpalpable, retroperitoneal disease) 
4 Minimal pulmonary metastases-less than five per lung field and the largest < 2 cm (non­
palpable abdominal disease) 
Moderate 
5 Palpable abdominal mass as only anatomical disease 
6 Moderate pulmonary metastases-five to ten pulmonary metastases per lung field and the 
largest <3cm or a mediastinal mass <50% of the intrathoracic diameter or a solitary 
pulmonary metastasis any size >2cm (nonpalpable abdominal disease) 
Advanced 
7 Advanced pulmonary metastases-mediastinal mass >50% of the intrathoracic diameter of 
greater than ten pulmonary metastases per lung field or multiple pulmonary metastases >3cm 
(nonpalpable abdominal disease) 
θ Palpable abdominal mass plus pulmonary metastases 
8.1 -minimal pulmonary 
8 2 -moderate pulmonary 
8.3 -advanced pulmonary 
9 Hepatic, osseous, or CNS metastases 
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In chapter II we performed an analysis of our patients with disseminated germ-cell 
tumors based on these classification models. We also looked for additional parameters 
that may be of use to predict the histological outcome of residual tumor after 
chemotherapy. 
3. Prognostic factors in prostate cancer 
Based on: Predicting treatment response in metastatic prostate cancer 
P.F.A. Mulders, F.M.J. Debruyne, G.O.N. Oosterhof 
Reviews on Endocrine-Related Cancer (1991), 38, 5. 
3.1 Introduction 
Prostate cancer is one of the major causes of death in older men in western 
countries. Epidemiological studies have shown that there is still an increase in the 
incidence of prostate cancer (Silverberg, 1989). In about 60-70% of the patients prostate 
cancer is diagnosed in an advanced stage (Catalona, 1986). Two major points of interest 
in the management of prostate cancer are the detection of the tumor in an early curable 
stage, when the disease is still localized, and the development of new treatment 
modalities for disseminated disease. 
Since more than 45 years, disseminated prostate cancer is treated with hormonal 
therapy (which is still the treatment of choice) (Huggins, 1941). However, at least 20-25% 
of the patients with metastatic disease do not react on hormonal treatment, and an equal 
percentage becomes resistant to the treatment within 2 years (Resnick, 1978). New 
therapeutic approaches are needed to prevent growth of both hormone-dependent and 
hormone-independent tumor cells from the onset, delarging time to progression and 
therefore improving survival (Grayhack, 1987). The results of treatment with combined 
hormonal and cytotoxic drugs were reviewed by several authors, but none of these have 
shown a substantial advantage, mainly because of limiting side-effects in these older 
patients (Gibbons, 1987). New therapeutic strategies are especially needed for the 
patients who are refractory to standard treatment. 
During the last years an increasing number of treatment modalities were 
developed for patients with disseminated prostate cancer. It was observed that the 
response to treatment and thus survival varies considerably in this group of patients. In 
order to be able to identify, before the start of treatment, the patients with a poor 
prognosis, it is useful to analyze the factors that influence survival. 
More knowledge on prognostic factors is also essential for the design of future 
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studies. They may give objective information on expected response to treatment and 
therefore on survival. Also the use of parameters which can monitor these new treatment 
modalities are essential and must be clarified with regard to the objective response of 
prostate cancer. 
This chapter aims to give an overview of clinical, pathological, radiographic and 
biochemical prognostic parameters and discuss their importance in predicting response 
directly related to progression and survival in patients with disseminated prostate cancer. 
3.2 Clinical prognostic parameters 
Age has been mentioned as a prognostic indicator (Berry, 1979, Wilson, 1984). It 
was concluded that, generally, younger patients had a more aggressive tumor, and 
therefore a worse prognosis than elderly patients. However, this is could not be 
confirmed by the results of others (Harrison, 1983, Emrich, 1985, Soloway, 1990, Ernst, 
1991). 
Another clinical parameter is the performance status, mostly categorized by the 
Karnofsky classification. De Voogt and associates showed this to be the most important 
prognostic indicator, and an increasing number of investigators confirmed this finding (de 
Voogt, 1989). A bad performance status is mostly associated with a shorter survival 
(Emrich, 1985, de Voogt, 1989, Soloway, 1990). This parameter is related with the 
advanced stage of the disease and it is useful in daily practice when treating patients with 
disseminated prostate cancer. Performance status as a factor in prognosis may be of more 
importance when used in combination with the pain score (Emrich, 1985). 
33 Pathological prognostic parameters 
As for pathological parameters, grade has been most frequently used to correlate 
histologic characteristics with biological activity. There are two widely used classifications, 
the Gleason and the Mostofi system. Both have been correlated with prognosis in 
prostate cancer (Gleason, 1974, Mostofi, 1975). During the last decades these 
classifications have been reconsidered, but they all share limited efficacy with regard to 
predicting response to treatment in the individual patient. Some studies show prognostic 
significance especially for the poorly differentiated tumors in all stages of prostate cancer 
(EI-Mahdi, 1983, Grayhack, 1983). De Voogt and Ernst indicated the positive prognostic 
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value of grade on survival (de Voogt, 1989, Ernst, 1991) 
Other types of histological parameters were looked for in order to predict 
response to treatment. First there are several studies on morphometrical aspects. The 
nuclear roundness factor initially showed interesting perspectives with regard to biological 
aggressiveness of the tumor (Diamond, 1982, Epstein, 1984). This potential prognostic 
parameter has not been used widely because the determination is time consuming and 
a significant variability is seen, related to tissue handling and preparation. On the other 
hand we believe that in the near future this parameter will be used again in more 
simplified and automated techniques and its use for the clinician will be re-established. 
Another prognostic approach is flowcytometry. Although much research has been 
done in this field, the results for prostate cancer are less promising than in other tumors 
(Schultz, 1985). Tannenbaum et al. found that the prognosis of these patients was related 
with ploidy (Tannenbaum, 1982). 
Recently a new prognostic parameter was described by Cohen and associates, who 
found a better survival in the patients without neuro-endocrine staining cells in their 
specimen (Cohen, 1990). This indicates that probably more results, derived from 
histologic and immunohistochemical examinations will follow and help us to individualize 
treatment in patients with prostate cancer. 
3.4 Radiographic prognostic parameters 
Bone is the only site of distant metastases in 65% of patients who present with 
disseminated prostate cancer (McCrea, 1988). Soloway et al. proposed a scheme to grade 
the extent of the disease observed on bonescan (Soloway, 1988). This classification 
opened the possibility to evaluate the number of bone metastases during hormonal 
treatment. Ernst et al. found that the extent of the disease on bonescan was the most 
important prognostic factor in their analysis (Ernst, 1991). Cooper and Soloway et al. 
found that the survival was worse with an increasing number of metastases on bone 
scintigraphy and proposed that this parameter should be used for prognosis (Cooper, 
1990, Soloway, 1990). 
3.5 Biochemical prognostic parameters 
Parameters determined from laboratory results have been examined extensively 
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during the last decades. Also because of economic reasons the establishment of these 
parameters is of great importance. In the majority of the investigations laboratory 
parameters have been compared with objective response on bonescan (Donoghue, 1978). 
The prognostic significance of alkaline phosphatase in patients with metastatic 
disease has been established, but is still underestimated (Wilson,1985). Prostate-acid-
phosphatase (PAP), is generally accepted to be of prognostic significance for survival 
(Babaian, 1986). However, more recent studies have shown that this parameter is of less 
value in disseminated prostate cancer, especially when compared to alkaline phosphatase 
and prostate specific antigen (PSA) (Killian, 1986, Haapiainen, 1990). This last tumor 
marker, first described by Kuriyama and Wang in 1981 (Wang, 1981), has become one 
of the most investigated biochemical tests for prognosis. PSA can be used for early 
detection of the disease, to establish time to progression and for monitoring the 
effects of treatment. PSA is not an appropriate marker in the sreening of prostate cancer 
due to its lack of sensitivity (Wang, 1981, Guiñan, 1987, Cooner, 1988). The role of PSA 
as a pretreatment prognostic parameter has not yet been established. In the original 
report of Kuriyama et al. a high level of PSA seemed to be associated with a poor 
survival, but these results were not significant (Kuriyama, 1981). PSA is, however, an 
extremely valuable marker in monitoring the tumor during treatment. Guiñan et al have 
established the significant value of PSA in monitoring patients with prostate cancer 
(Guiñan, 1987). Cooper et al. showed that prognosis is good in patients with a very low 
PSA (< 10 ng/ml) six month after the start of hormonal treatment, but he used this 
factor in a combination with bone scanning (< 15 lesions) to obtain significant results 
(Cooper, 1990). 
Other laboratory parameters than the above mentioned are less investigated. 
Soloway recently described the value of pretreatment testosterone level (Soloway, 1990). 
A low testosterone level before the start of treatment was associated with a shorter 
survival. In a multivariate analysis he used this factor together with the performance 
status and number of bone lesions to obtain significant prognostic groups (Soloway, 
1990). Also other investigations showed that patients with low pretreatment testosterone 
levels were less responsive to androgen deprivation (Harper, 1984, Ernst, 1991). 
In table 6 we summarize the most frequently used prognostic parameters in 
disseminated prostatic cancer. 
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Table 6: + = significant correlation, · = no significant correlation 
, \, age 
performance 
status 
Hb , 
PSA 
, PAP 
AlkP 
testosterone 
grade 
number of 
bone 
metastases" 
Berry 
79 
n=aa 
+ 
+ 
+ 
+ 
Emrich 
•as -
0=1020 
-
+ 
+ 
+ 
+ 
-
cfe Voogt 
'89 
n=436 
+/-
+ 
+ 
+ 
+ 
+ 
Soloway 
'90 
n=110 
-
+ 
-
+ 
+ 
Ernst 
' '91 
n=162 
-
-
-
-
+ 
-
+ 
Patients with disseminated prostate cancer who fail the initial hormonal treatment 
have a mean survival of less than one year (Catalona, 1986). There are several 
hypotheses 
for this failure to response to hormonal treatment. The presence of heterogeneous 
clones of carcinoma cells is mostly accepted as being the cause of this phenomenon 
(Isaacs, 1981). From the onset of the malignancy there must be hormone-dependent and 
hormone-independent cells in the tumor. During the initial hormonal treatment, 
hormone-independent cells continue to proliferate and later become evident as tumor 
progression. Another hypothesis is the change of the individual cells in their genetic 
requirements of androgen for growth, which can result in hormonal resistance (Isaacs, 
1981) 
Because of the low efficacy and considerable side-effects there is still limited place 
for chemotherapy in the treatment of hormone resistant prostate cancer (Tannock, 1985). 
This is also the reason why much research has been done on "salvage" endocrine 
manipulation. Despite the number of investigations in this field, it can be concluded that 
no evidence for prolonged survival could be established. The only rationale for using 
second-line hormonal treatment is the subjective improvement in 20 to 30%. (Narayama, 
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1981, Williams, 1986). It is difficult to predict which patient will react on salvage 
endocrine treatment. Serum testosterone levels may indicate the failure of a 
primary hormonal treatment, and the patient may have benefit from a bilateral 
orchiectomy. Geller et al. showed the usefulness of determining the DHT concentration 
in prostate tissue (if greater than 2.4 mg/gm), because it can indicate persistent androgen 
production which may react on secondary hormonal manipulation (Geller, 1984). The 
most important problem of predicting reaction on secondary hormonal manipulation is 
the lack of follow-up, due to the limited duration of response. 
In conclusion we are convinced that treating patients with disseminated prostate 
cancer with standard therapy is not in accordance with the heterogeneity of the tumor. 
Factors predicting response to treatment can be determined from clinical, pathological, 
radiographic and laboratory parameters. Further studies of the alreadey known 
parameters and the development of new parameters are necessary. For this reason we 
performed side studies of trials on hormonal treatment for disseminated prostate cancer 
which were organized by the Dutch South Eastern Oncology Group. These trials are well 
monitored and therefore accessible for prognostic factor analysis. The results are shown 
in chapter III and IV. 
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4. Prognostic factors in bladder cancer 
4.1 Introduction 
Bladder cancer is one of the most prevalent cancers in male, especially because 
of the high recurrence rate (Silverberg, 1987). Tumors of the bladder are mainly divided 
into superficial and muscle-invasive cancers, each with its own clinical consequences. 
Approximately 85% of bladder cancers present as superficial tumors (American Cancer 
Society, 1987). Superficial bladder tumors are considered as a homogeneous group with 
consequences for the treatment and the follow-up shedule. 
Because of the high incidence most studies concentrate on superficial bladder 
cancer, in an attempt to decrease the recurrence rate and to prevent progression into 
muscle-invasive disease. One of the most important features of the superficial bladder 
tumor is the high incidence of recurrence following initial transurethral tumor resection. 
Recurrence rate ranges from 50 to 80% (Lutzeyer, 1982). This is because the disease is 
considered to affect the whole urethelium. Every new, in onset superficial tumor, may 
progress into an invasive cancer. This risk is estimated to be 25-30% (Heney, 1983). This 
means that the follow-up of a patient with superficial bladder cancer is a continuous 
process and that the patient remains under surveillance during the rest of his life. 
The high tendency to recur and the risk of progression into invasive disease is the 
ratio for studies on new treatment possibilities, especially new intravesical therapies. 
Many prospective randomised studies have been performed since the first report on the 
beneficial effects of intravesical chemotherapy by Jones and Swinney and Veenema 
(Jones, 1961, Veenema, 1969). The importance of intravesical chemotherapy and later 
of intravesical immunotherapy is now established. In the past it was mainly used after 
inclompete resection of a tumor and in case of carcinoma in situ (Morales, 1981, Edsmyr, 
1984, Jakse, 1984). During the last years more attention was given to the prophylactic use 
of intravesical chemotherapy and especially immunotherapy (Morales, 1978, Koontz, 
1981, Lamm, 1985, Herr, 1986). Today there is consensus about the beneficial effect of 
this treatment on superficial bladder tumors and carcinoma in situ with regard to the 
decrease of recurrence rates (Herr, 1987, Kurth, 1989). On the other hand it appeared 
that not all the superficial bladder tumors react the same on this treatment (Herr, 1991). 
Some superficial bladder tumors with a high tendency for recurrent and progressive 
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disease did benefit more from the adjuvant treatment. On the other hand for some other 
less aggressive tumors intravesical therapy appeared to be of no use. This is why 
individualization of treatment is mandatory (Rubben, 1988). 
Considering the new developments in the treatment of superficial bladder cancer, 
the research on prognostic factors is essential. Prognostic factor analysis may lead to the 
formation of certain risk groups with consequences for the choice of treatment (Herr, 
1989). Within this chapter we want to summarize the prognostic factors which are of 
interest for superficial bladder tumors. 
4.2 Clinical prognostic parameters 
Possible clinical factors like age and sex have been determined, but no clear 
prognostic value has been found (Pocock, 1982, Narayama, 1983, Herr, 1989). 
The patient with a superficial bladder cancer is mostly not suffering physically 
from the tumor; this means that it is not relevant to examine features like weight-loss, 
performance status and pain. 
In bladder cancer, a radiographic characteristic like the dilatation of the ureter on 
intravenous urography may indicate muscle invasive disease and therefore a worse 
prognosis (Hatch, 1986, Golding, 1987). 
One of the most important independent prognostic factors for recurrent disease 
is the multiplicity of the tumor. In several studies this appeared to be of major 
importance (Lutzeyer, 1982, Dalesio, 1983, Parmer, 1989, Kurth, 1989). This 
characteristic is already included in the design of several new trials. The size of the 
largest tumor as a prognostic factor is controversial. In contrary with Lutzeyer et al. and 
Kurth et al., who found no prognostic impact, several other investigations included this 
factor as a positive prognostic sign (Lutzeyer, 1982, Heney, 1982, Dalesio, 1983, Kurth, 
1989, Parmer, 1989). 
4.3 Pathological prognostic parameters 
The importance of urine cytology in the detection and follow-up in patients with 
bladder cancer has been established (Lewis, 1976, Murphy, 1984, Koss, 1985, Meuleman, 
1988). Especially the occurrence of the combination of a positive cytology and a high 
grade bladder tumor is striking (Koss, 1985, Meuleman, 1988). Supplementary tests with 
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cytology like transferrin receptor expression and quantitative immunocytology show 
adequate predictive value on risk for recurrence (Smith, 1990, Huland, 1990). 
One of the most important classification models derived from histologic features 
is the TMN classification (IUCC, 1987). The ultimate goal of this system was to 
standardize the subdivision of patients with bladder cancer and consequently make them 
accessible for treatment comparison (Prout, 1977). Retrospective analysis on subdivisions 
of patients could be performed (Cifuentes Delatte, 1982). An important modification for 
superficial pT, tumors was developed by the seperation pT. and PT, (Chisholm, 1980). 
The significance of lamina propria invasion (pT,) on prognosis was indicated 
(Anderstrom, 1980). It was questioned whether pT, tumors should still be classified as 
"superficial" and if they had to be treated with another strategy (Heney, 1982). Today 
tumor stage is included in every prognostic analysis of superficial bladder tumors. 
Especially with regard to the natural history of bladder tumors, tumor-stage appeared to 
be of significant prognostic value (Heney, 1982, Lutzeyer, 1982). However, when treated 
with intravesical instillations of especially BCG, tumor stage distinction between pT, and 
pT, showed to be of less prognostic significance (Shinka, 1990). These instillations can 
alter the biological behaviour of high risk tumors and influence the prognosis. Torrence 
et al. did not find a significant influence of tumor stage on recurrence-free interval 
(Torrence, 1988). 
Grade is a histological feature which has shown its usefulness in the management 
of superficial bladder tumors. Its application on bladder tumors was already performed 
in 1922 (Broders, 1922). Histological typing of bladder tumors has been introduced as a 
classification system by Mostofi (Mostofi, 1973). A clear relation between grade and 
prognosis was shown (Gilbert, 1978). Malkowics et al., after evaluation of the influence 
of the grade on prognosis, advised to treat high grade superficial bladder cancers more 
aggressively with radical cystectomy (Malkowics, 1990). However, restrictions of the value 
of grade must be made because different interpretations of grading by different 
pathologists became obvious, and this inter-individual variation will have consequences 
in clinical decision making (Ooms, 1983). Therefore, objective criteria derived from 
quantitive histological features are of importance. Attempts have been made to increase 
the usefulness of histologic grading as a prognostic factor in patients with bladder 
carcinoma (Pagano, 1987, Pauwels, 1988). 
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A combination of stage and grade appeared to be of importance for prognosis 
(Kern, 1984). Especially the pT,G3 tumors are at risk for recurrent disease and this 
unfavourable outcome is discussed in several studies (England, 1981, Jakse, 1987, Abel, 
1988, Birch, 1989, Jenkins, 1989). 
Another characteristic which is possibly associated with prognosis is the histology 
of the associated random biopsies. The results of biopsy of normal-looking mucosa 
appeared in several studies to be of influence on recurrence (Loening, 1978, Soloway, 
1978, Smith, 1983, Wolf, 1983). It is an indication that bladder cancer affects the total 
urothelial surface. This also explains why, especially patients with carcinoma in situ, 
require adjuvant treatment like intravesical chemotherapy or immunotherapy to decrease 
the risk for recurrent disease (Herr, 1983, Quilty, 1987). 
Table 7 summarizes the most important clinical and histological prognostic factors 
that are of interest in the treatment of superficial bladder cancer. 
Table 7: + = significant correlation, - = no significant correlation 
History Of 
recurrence 
Multiplicity 
size of tumor 
T-siage 
Grade 
Luizeyer 
'82 
n=3ts 
+ 
+ 
+ 
+ 
Dalesio 
'83 
n=3oa 
+ 
+ 
+ 
(only T,) 
+ 
Heney 
*B2 
«=249 
+ 
+ 
+ 
+ 
Parmèr 
'89 
n=379 
+ 
+ 
-
+ 
Kurtrt 
189 
n=371 
+ 
+ 
-
+ 
+ 
4.4 Biochemical and cytogenic prognostic parameters 
Because superficial bladder tumors form a heterogeneous group in their clinical 
course, studies on adjuvant prognostic factors remain essential. Until now no additional 
prognostic value is derived from laboratory results which can be used in daily clinical 
practice. The usefulness of features like blood-group antigens, specific red cell adherence, 
receptor status, T-antigens and other monoclonal antibodies have shown prognostic 
significance, but so far no widespread clinical application has been achieved (Stein, 1981, 
Fradet, 1986, Srivinas, 1986, Blasco, 1988). It is, however, essential to continue the search 
for factors that can be of use for the routine evaluation of patients with bladder tumors. 
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In the last decade flowcytometry has been developed as an objective method for 
determination of the recurrence-free interval. Several studies describe that additional 
information for the prognosis may be derived from flowcytometry (Hadjissotiriou, 1985, 
Masters, 1986, Blomjous, 1988). Murphy et al. underlined that the routine use of the 
flowcytometric technique remains controversial, because no strong additional prognostic 
potential could be found, as compared to routine cytological and histological grading 
(Murphy, 1986). 
Another factor which has been evaluated is morphometry. Recently, studies 
have shown that morphometric criteria are superior to flowcytometry, as an additional 
feature for patients with superficial bladder tumors (Ooms, 1981, Lipponen, 1990). 
Routine use of this time-consuming technique is not yet appropriate. The role of 
abnormal chromosomal markers with regard to prognosis of superficial bladder cancer 
has been subject of investigation (Sandberg, 1977, Falor, 1988). Although the results are 
promising, the usefullnes for predicting prognosis in clinical practice remains uncertain. 
Patients with superficial bladder cancer are characterized by their heterogeneous 
clinical course and unpredictable reaction on treatment. Prognostic factor analyses are 
useful to individualize treatment and to achieve the best possible outcome for these 
patients. Superficial bladder tumors are not aggressive in their neoplastic behaviour and 
research is concentrated on the high recurrence rate in some of these tumors. The 
consensus on the positive effect of intravesical immuno-, and chemotherapy after initial 
transurethral resection of all visible tumor has changed the approach of bladder tumors 
considerably. When different treatment options exist, there is a need for an adequate 
indication to choose the right treatment schedule. Prognostic factor analysis show 
different results in patients treated with or without adjuvant therapy. Review articles and 
consensus meetings are important in order to define standard treatment and follow-up 
shedules and to initiate the design of multicentre studies (Cutler, 1982, Abel, 1988, 
Soloway, 1989). 
Within this prospect, in Chapter V we performed a prognostic analysis of a 
controversial subgroup of superficial bladder carcinomas. Chapter VI describes a 
prognostic analysis of superficial bladder carcinomas treated with intravesical instillations, 
indicating the importance of side-studies on prognostic factors in every clinical trial. 
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5. Prognostic faeton in renal cell carcinoma 
5.1 Introduction 
Renal cell carcinoma (RCC) is characterized by its unpredictable behaviour and 
tendency to recur and metastasize even several years after diagnosis. It is a neoplasm 
with, in general, an unfavourable prognosis. Thirty percent of the patients already have 
metastases at the time of diagnosis and only 50% of the patients present with a localized 
disease and have a chance to be cured (de Kernion, 1978). Depending on the stage of 
the tumor, the 5-years survival rate ranges from 30 to 60% (Holland, 1973). In metastatic 
disease the prognosis is very poor with a one year survival of 26% (Patel, 1977). 
Surgery remains the corner stone in the treatment and represents the starting 
point. It remains the only possibility for cure in patients in whom the tumor is confined 
to the kidney. Patients with advanced disease at the time of diagnosis suffer from the 
consequences of incurability. Therefore, patients with disseminated cancer need adjuvant 
treatment to improve survival. 
The efficacy of adjuvant treatments like chemotherapy and immunotherapy still 
has to be elucidated further. Especially immunotherapy has shown promising results 
(Horoszewics, 1989, Muss, 1991). These therapeutic options with low response rates have 
the disadvantage of considerable side effects in patients who are often already physically 
disabled by the metastatic disease. Strict indication for adjuvant treatment is therefore 
of importance in order to avoid useless and harmful treatment. 
With the use of prognostic factor analysis we are able to individualize the 
treatment of cancer patients. From the onset of treatment, it became clear that not all 
had the same clinical course. Several staging systems have been developed and tested for 
practical use in order to predict the clinical course of each patient. The staging system 
initiated by Flocks and Kadesky and popularized by Robson and associates, appeared to 
be a reliable indicator for survival (Flocks, 1958, Robson, 1969). Another staging system 
which includes the descriptive tumor, nodes, and metastases (TMN) characteristics has 
been developed by the International Union against Cancer and appeared in its last 
edition in 1987 (Beahrs, 1988). A comparison of the two classification systems with the 
TMN stages is shown in Table 8. 
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Table 8 Comparison of the two classification systems with the TMN stages 
TNM IUCC Robson 
Small tumor, no enlargement of kidney 
Large tumor, cortex not broken 
Perinephric or hilar extension 
Extension to neighbouring organs 
Nodal invasion 
Renal vein involved 
Vena cava involved 
Distant metastases M+ 
T1 
T2 
T3 
T4 
N+ 
V1 
V2 
1 
2 
3 
3 
3 
3 
3 
A 
A 
В 
D 
С 
С 
С 
The applicability of these systems has been subject to several investigations, and 
in different subsets of patients they appeared to be good predictors for survival (Bassil, 
1985, Hermanek, 1990) Especially the IUCC staging system is a reliable indicator of the 
extent of the tumor (Hermanek, 1990). Classification systems are therefore at the basis 
of treatment in clinical practice. As adjuvant therapy becomes increasingly popular, the 
ability to identify patients at risk for progression is critical. Another advantage of the use 
of a standardized classification model is the ability to exchange treatment results. The 
classification models are also used for a more precise prognostic factor analysis. It is 
important to determine whether these new factors are of additional prognostic 
significance to the prognostic characteristics already known. 
5.2 Clinical and biochemical prognostic parameters 
Gender has been indicated as a prognostic parameter. McNichols et al. observed 
a better survival in women with RCC (McNichols, 1981). The same was seen in an 
investigation in young (20 to 40 years) patients (Lieber, 1981). This is in contradiction 
with Selli et al., who could not find any relation (Selli, 1983). 
Age is also not a clear prognostic parameter. Griffith said that "the extremes of 
age are usually regarded as of bad prognostic import, youth because of increased activity 
in the growth, and old age from the shorter natural extension of life" (Griffith, 1964). 
This is confirmed m some investigations where a worse prognosis was seen in elderly 
patients (Selli, 1983). However, Neves et al. did not found any relationship between age 
and survival (Neves, 1988). 
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The symptoms of patients with RCC varies. Performance status has been 
described for several decades as a measure for the evaluation of the effects of 
chemotherapeutic drugs (Kamofsky, 1949). Also, in patients with metastatic RCC the 
performance status proved to be a powerful independent prognostic factor (Maldazys, 
1986). Another symptom which showed to be of prognostic significance is a history of 
weight-loss. In several studies this event, which occurs before the diagnosis is established, 
showed to be a bad prognostic sign (Lieber, 1981, Selli, 1983, Neves, 1988). Fever at the 
time of diagnosis is also, though rarely mentioned, a bad prognostic feature (Lieber, 
1981). 
From the laboratory results some prognostic parameters were obtained. Especially 
erythrocyte sedimentation rate (ESR) has been investigated for a long period. Several 
investigators described a worse prognosis in patients with an elevated ESR at the time 
of diagnosis (Bech Hansen, 1972, Hannisbal, 1989). However, this could not be confirmed 
by Lieber et al. in their selected young adult population (Lieber, 1981). In an 
investigation done by Chasan et al. the level of serum calcium was of no influence on 
survival (Chasan, 1989). 
5.3 Anatomical prognostic parameters 
Nephrectomy will be performed in almost every patient suspected to have a RCC. 
In case of a localized tumor, nephrectomy is mandatory in order to obtain cure for the 
patient. In more advanced cancers a debulking operation may be beneficial for local 
control of the neoplasm or as a basis for protocols on adjuvant treatment (Golimbu, 
1986A, Horoszewics, 1989, Giuliani, 1990). 
As has been mentioned in the introduction of this chapter the basis of dividing 
patients in prognostic groups is the TMN classification system. Numerous reports 
obtained positive prognostic significance for tumor stage, or the presence of metastases 
in bone, soft tissues and lymphnodes (Fuselier, 1983, Nurmi, 1984, Bassil, 1985, Golimbu, 
1986A). 
In a report from Priestly, published in 1939, tumorweight showed to be of 
prognostic significance (Priestly, 1939). Nowadays the relation between tumor size and 
clinical behaviour of the carcinoma is clear. This finding was already mentioned in 1970 
(Bottiger, 1970). Size of the primary tumor is also obviously a predictor for the risk of 
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metastasis (Fuhrman, 1982). 
In every study concerning prognosis the M-stage has been mentioned as the 
strongest factor (Siminovitch, 1983). Also the site of the metastases appeared to be of 
prognostic significance. Patients with lung metastases only, react better on chemo- or 
immunotherapy than patients with metastasis to other single organs (e.g. bone) or 
multiple organs (de Kernion, 1983). Therefore the survival of patients with only lung 
metastases is better (Maldazys, 1986). 
Another feature, which has been clarified, is the bad prognostic sign of regional 
lymphnode metastases (Middleton, 1973). Several investigation found a positive effect of 
a radical lymphadenectomy on prognosis (Giuliani, 1990). This effect on prognosis, 
however, is still controversial. 
One of the supplements of the TNM classification model, which is included in the 
IUCC staging model of 1987, is the renal vein involvement. The relation between renal 
vein involvement and risk on distant metastases and therefore the influence on survival 
has already been mentioned in 1953 (Throckmorton, 1953). The extent of this 
involvement adversely affects prognosis in several investigations (Skinner, 1971, 
Siminovitch, 1983). Also invasion of the vena cavai wall seems to be a bad prognostic 
sign. However some other investigations found no additional prognostic information of 
renal vein involvement on survival (McNichols, 1981, Fuselier, 1983, Nurmi, 1984, Ferrari, 
1990). It is now clear that the survival rate of patients with vena cava involvement is not 
worse if it can be removed radically (Golimbu, 1986B, Hatcher, 1991). 
5.4 Pathological, cytogenic and karyomehic prognostic parameters 
The histology of renal cell tumors must imply the definition of carcinoma. Grawitz 
gave the first definition of this carcinoma (RCC), using embryological and architectural 
characteristics (Grawitz, 1884). Later, the differentiation into other cell-types, like 
adenomas, sarcomas and oncocytomas, have been studied (Foot, 1951). Of course these 
differentiations will have implications on prognosis. It is therefore that we restrict the 
"renal tumor" only to the true carcinomas (RCC). Within this group certain histological 
characteristics are of prognostic importance. The prognostic significance of histological 
grade has been known for over fifty years (Priestly, 1939). In the beginning of this century 
grading according to Hand and Broders was done, and this appeared to have implications 
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on survival (Hand, 1932). Most grading systems are nowadays according to the WHO 
(Mostofi, 1981). This describes nuclear atypia, including the size of nucleoli, 
supplemented by some cytoplasmic features. It appears, however, that this grading system 
suffers to some degree from interobserver variability. It is probably for this reason that 
modifications have been developed in an attempt to simplify the criteria of grade (Foot, 
1951, Skinner, 1971). The use of various grading systems, accepted so far in the practice 
of pathology, will not be beneficial for comparison of results. Another problem in grading 
is the heterogeneity of the tumor. When several sections of one tumor are investigated, 
there is often a great variability in morphology from section to section. It is also for this 
reason that the importance of grade for prognosis is diminishing. This problem with 
histological characterization is a challenge for many investigators to simplify the grading 
system. Reis et al. looked for a more reproducible way of grading by using 
the histologic pattern as a prognostic factor (Reis, 1988). The implications on prognosis 
of these architectural patterns are however controversial, especially for papillary 
neoplasms and carcinomas which are predominantly composed of granular cells (Fryfolge, 
1948, Murphy, 1965, Mancilla-Jiménez, 1976, Fuhrman, 1982). However there are some 
characteristics which are related to survival: patients with spindle carcinomas have a poor 
prognosis (Tornera, 1983). Medeiros et al. showed a clear relation between various cell 
types and grade, and described an influence on survival (Medeiros, 1988). In a recent 
report Delahunt et al. showed a new histologic marker, the nucleolar organizer region, 
which is visible by electron microscopic examination and appeared to be of prognostic 
significance (Delahunt, 1991). It can be expected that in the near future more of these 
features will be described and may become of use in daily clinical practice. 
A new tendency in histologic characterization is the nuclear morphometry. 
Morphometric analysis has been used successfully to asses the outcome of patients with 
malignancies when standard pathologic grading systems failed. Several parameters were 
investigated, including nuclear elongation, nuclear roundness, nuclear crowding, mitotic 
density and tumor grade, and evaluated for their accuracy in predicting prognosis. Several 
reports showed a positive correlation between these various morphometric parameters 
and survival in a subdivision of patients with stage I disease (Tosi, 1986, Bibbo, 1987, 
Murphy, 1990). Gilchrist et al. described nuclear size as a prognostic factor in all RCC 
(Gilhirst, 1984). They concluded that larger nuclei were related with a shorter survival. 
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Flowcytometiy is known as an easy and reproducible method to determine 
deoxyribonucleic acid (DNA) content. This technique can be used in every clinical 
practice. Otto et al. concluded in their study a positive indication of the DNA content on 
risk for recurrence and advised adjuvant therapy after nephrectomy in bad risk selected 
patients (Otto, 1984). A higher prognostic significance could be obtained when combining 
flowcytometiy with nuclear grading. DNA content in RCC might be a superior prognostic 
indicator than other clinical and microscopical parameters (Ljungberg, 1986). These 
results were confirmed by Rainwater et al. in a study with a long follow-up (Rainwater, 
1987). On the other hand, another investigator could not find a prognostic significance 
of flow cytometry as a significant TMN stage-independent impact on prognosis and re­
opened the discussion about the widespread clinical application of ploidy status (Currin, 
1990). 
With all the prognostic factors known today it still not possible to predict the 
outcome of patients with a RCC correctly. To get a better insight in the value of each 
prognostic factor a review of all clinical and histological parameters is mandatory, and 
especially an evaluation of each value is of interest. 
Table 9 shows an overview of the mostly used prognostic parameters in RCC. 
Table 9: + = significant correlation, - = no significant correlation 
sex 
age 
weight 
toss 
τ -
η • 
M 
ν '. 
tumor 
size" 
grade 
cell type 
McNichols 
'81 -
n=506 
+ 
+ 
+ 
-
+ 
-
Fuselier 
. 'fla ' 
П=161 
-
+ 
+ 
+ 
-
+ 
-
Sem 
'83 , 
n=115 
-
+ 
+ 
+ 
+ 
-
+ 
+ 
Sîmînovit 
'83 
η=24θ 
+ 
+ 
+ 
+ 
Nurmî 
'84 
π=257 
-
-
+ 
+ 
+ 
+ 
-
+ 
-
Bassil 
'85 
π=252 
+ 
+ 
+ 
+ 
Storkel 
'89 
n=43T 
+ 
+ 
+ 
+ 
. Giuliani 
, '90-
,- n=2QO 
+ 
+/-
+ 
+ 
+ 
+ 
_ 
In chapter VII an overview of all possible prognostic factors, which can be used 
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in daily clinical practice for patients with RCC, is given. By using the results of chapter 
VII a study of a low-risk group of patients with RCC is performed in order to detect the 
patients at risk. The results are shown in chapter VIII. 
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SUMMARY 
Following chemotherapy for disseminated testicular cancer, 55 patients underwent 
surgery because of residual tumour. The histological findings were viable tumour in 12 
patients, mature teratoma in 12 and fibrosis and/or necrosis in 31. Retroperitoneal 
abdominal masses were evaluated radiographically before and after chemotherapy. The 
reduction in size of these masses after chemotherapy appeared to have prognostic 
significance. A decrease of more than 70% was always associated with fibrosis. A residual 
mass over 50 mm indicated viable tumour or mature teratoma. Seminoma or embryonal 
carcinoma was more likely to result in fibrosis/necrosis in the resected tissue. Both the 
Indiana and the EORTC classification models can be used for prognosis. 
Radiographic measurements before and after chemotherapy are of considerable 
prognostic significance. These objective indicators help in planning treatment and so 
diminish side effects of therapy and maintain or even increase the high cure rate in 
disseminated testicular cancer. 
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INTRODUCTION 
Testicular cancer should now be curable even in an advanced stage. Cure rates 
of 70-80% have been reported for disseminated germ cell tumors of the testis. The 
introduction of cisplatin-based combination chemotherapy has increased cure rates 
dramatically (1,2). Improvements in staging methods and surgical techniques are also 
relevant to cure rates (3,4). Despite the encouraging results, we need a better insight into 
the timing and extent of the different phases of treatment. 
The European Organization for Research and Treatment of Cancer (EORTC) 
classification of prognostic factors and the Indiana classification of extent of disease, 
define risk factors for individual patients at the start of treatment (5,6). The number of 
cycles of chemotherapy is, however, usually prearranged and sugsequent surgery is 
standard when residual tumour is present. 
The purpose of this study was to look for other prognostic factors that might help 
to define a more individual treatment schedule and thus to diminish the side effects of 
therapy and increase cure rates. 
PATIENTS AND METHODS 
Between January 1979 and January 1988, primary chemotherapy was given to 61 
patients with disseminated germ cell tumours. The histology of the primary tumour was 
non-seminoma in 46 cases and seminoma in 15. 3 of these were extragonadal tumours. 
The extent of disease was established according to the Royal Marsden classification (7). 
Included were stages lie, III, and IV. Chemotherapy before surgery consisted of 4 or 
more cycles of cisplatin-based combination therapy (cisplatin, vinblastine, bleomycin 
(PVB), bleomycin, etoposide, cisplatin (ВЕР) or PVB and ВЕР alternating); 51 patients 
received 4 cycles of chemotherapy; 10 patients received up to 8 cycles before surgery 
because tumour markers remained high. The patients were staged retrospectively 
according to the Indiana classification of extent of disease and the EORTC classification 
of prognostic factors (5,6). 
After chemotherapy, all patients were evaluated by clinical, biochemical, and 
radiological examination. Biochemical assessment included serum a-fetoprotein (a-FP, 
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normal <20 ng/ml) and human chorionic gonadotropin (ß-HCG, normal <3.0 ng/ml). 
Radiological examination consisted of abdominal computed tomography (Siemens 
Samatron DR3), chest X-ray and lung tomography. Radiological re-evaluation was done 
by one radiologist (C.B.). The cure rate, 3-year survival rate and histopathological 
outcome of surgery were established in relation to the 2 classifications. Following 
chemotherapy, surgery was performed in the 55 patients with residual tumour. Residual 
mass was defined as nodes >10 mm and/or residual strands on computed tomography. 
Five patients had no residual mass after chemotherapy and normal tumour markers; they 
were followed up closely. One patient died soon after establishment of the diagnosis. The 
operation in patients with residual mass after chemotherapy consisted of retroperitoneal 
lymph node dissection (RPLD) in 44 patients, thoracotomy in 6 and both in 5 patients. 
Resected residual tumours were examined histologically. Patients with fibrosis or mature 
teratoma were followed up closely at lengthening intervals. Patients with viable tumor in 
the resected tissue were given additional chemotherapy. 
The size of metastatic tumour before and after chemotherapy was measured 
radiologically (largest transverse diameter) and compared with histopathological 
assessment. 
Cure was defined as absence of biochemical or radiological evidence of disease 
after chemotherapy or as a surgical finding of fibrosis or mature teratoma (the latter only 
if all residual tumour mass had been removed). 
Follow-up ranged from 5 months to 8 years (mean 3 years). 
The accuracy of the classifications was analysed statistically by the Kaplan-Meier method 
for survival and cure rates, and significance was estimated with trend tests. Differences 
in histologic outcome were analysed with the chi-square test; in the case of continuous 
variables, the Kruskal-Wallis test was used. 
RESULTS 
The overall 3-year survival rate of 61 patients with disseminated germ-cell cancer 
was 78% and the cure rate 72%. Patients were placed in the subgroups of the EORTC 
classification (good, moderate or bad prognosis) and of the Indiana model (minimal, 
moderate, advanced disease). Survival and cure rates were calculated for the patients in 
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the subgroups of the 2 classifications (Tables 1 and 2). Both methods of classification 
correlated well with cure and survival rates. 
-EORTC 
- Indiana 
good 
moderate 
poor 
minimal 
moderate 
advanced 
No. 
1β 
30 
13 
17 
28 
16 
Table 1 Prognostic Classification and Cure Rate 
-EORTC 
- Indiana 
. good 
moderate 
poor 
minimal 
moderate 
advanced 
Table 2 Prognostic Classification 
No. 
18 
30 
13 
17 
28 
16 
and Survival 
cure rate (%) 
84 
77 P=0.029 
62 
88 
79 P=0.017 
69 
3-years survival (%) 
100 
78 P=0.006 
51 
89 
76 P = 0.09 
69 
The histologic assessment of specimen was of great importance for 3-year survival: 
31 patients had fibrosis or necrosis or both, 12 had mature teratoma, and 12 had viable 
tumour. The 3-year survival rates for these groups are shown in Table 3. The histology 
of the primary tumour was important for the results of surgery; seminoma or embryonal 
cell carcinoma was more likely to produce fibrosis or necrosis (Table 4). Two patients 
with fibrosis died: 1 from brain metastases and 1 from a malignant Leydig -cell tumour. 
Only 1 patient died post-operatively after resection of a 30-cm abdominal tumour 
(mature teratoma). Of the 12 patients with viable tumour in the residual mass, 7 died 
from testicular cancer. The 5 patients with no residual tumour after chemotherapy and 
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who were not operated on are still alive with no evidence of disease. 
No 3-years survival rate (%) 
Fibrosis 31 93 
Teratoma 12 92 P<0 001 
Tumour 12 27 
Table 3 Histological Results and Survival 
No. 
Seminoma 9 
Malignant teratoma undifferentiated 4 
Malignant teratoma 1 
Malignant teratoma trophoblastic 1 
Table 4 Histology of Primary Tumour in Fibrosis Group 
The relative reduction in tumour mass after chemotherapy had great significance. 
The median decrease was 70% in patients with a histological outcome of fibrosis and 
28% in the group with mature teratoma or tumour (Table 5). The difference was 
statistically significant. 
Fibrosis 
Teratoma 
Tumour 
P= 
median size (mm) before 
Chemotherapy Surgery 
75 
63 
100 
=0 08 
20 
53 
53 
P<0 001 
Median difference 
Absolute Relative 
(mm) (%) 
40 
3 
40 
P=0 003 
70 
10 
50 
P<0 001 
Table 5 Size of Tumour and Results of Operation 
In 5 patients the abdominal mass increased during chemotherapy; 4 had mature 
teratoma and 1 had viable tumour. We found that a reduction of more than 70% was 
always associated with a histological report of fibrosis (Table 6). 
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Decrease 
>30% 
>50% 
>70% 
No. 
36 
24 
15 
Fibrosis 
28 
19 
15 
Teratoma 
2 
2 
0 
Tumour 
6 
3 
0 
Table 6 Relative Decrease on CT Scan and Histological Assessment 
The size of residual mass after chemotherapy and the histological assessment are 
shown in Table 7. Even in small residual tumours, viable tumours could be found, 
although rarely. Large residual tumors were more likely to contain mature teratoma or 
viable tumour. This was always the case for residual masses >50 mm. 
Size 
(mm) 
0-20 
21-30 
31-50 
>50 
Total 
No. 
20 
9 
9 
9 
47 
Fibrosis 
(%) 
85 
78 
56 
0 
62 
Teratoma 
(%) 
10 
11 
22 
55 
22 
Tumour 
(%) 
5 
11 
22 
45 
16 
Table 7 Size and Histological Assessment 
When Table 5 and 6 are combined, the results shown in the Figure are obtained. 
Elevated tumour markers (a-FP and/or ß-HCG) following chemotherapy were also of 
prognostic importance. Three patients with persistently high a-FP or ß-HCG after 
chemotherapy underwent surgery. They all had viable tumour in the resected tissues, but 
9 patients with normal levels tumour markers still had viable tumour in the resected 
tissues. 
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Fig 1: size of the abdominal mass before and after chemotherapy 
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DISCUSSION 
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Disseminated testicular cancer can be cured in most cases with a combination of 
chemotherapy and surgery. It is, however, difficult to predict the results of treatment in 
individual cases. The EORTC classification of prognostic factors and the Indiana 
classification of extension of disease attempt to categorise patients in order to predict the 
efficacy of treatment. Multivariate analysis leads to the formation of prognostic groups 
that indicate response rates and survival rates (5,6,8,9). In the present series the EORTC 
classification was more appropriate. Standard therapy for disseminated testicular 
carcinoma is the same, whatever the risk: 4 cycles of combination chemotherapy 
eventually followed by resection of residual mass. The detection of prognostic factors 
should result in more individualised treatment. 
Individualised chemotherapy might consist of fewer cycles for patients with good 
prognostic factors and more cycles (with more effective and probably more toxic 
chemotherapy) for those at high risk. 
With regard to the best individual treatment, the role and timing of cytoreductive 
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surgery are of special interest. Standard treatment includes surgery when a residual mass 
remains after chemotherapy (10,11), but should every patient with a residual tumour, 
however small, undergo surgery? 
Survival rates depend largely on the histology of resected specimens (12,13). A 
patient with residual viable tumour or mature teratoma should undergo surgery in order 
to reduce the size of the tumour and make it accessible to secondary chemotherapy, since 
it could grow or become malignant again (14,15). Fibrosis or necrosis need not to be 
resected. 
Donohue et al showed that histology of the primary tumour was an important 
prognostic sign for the RPLD (16). Tumours without teratomatous elements were more 
likely to lead to fibrosis in the resected tissue. Our data also show that the absense of 
teratomatous elements in the primary tumour are more likely to produce fibrosis in the 
residual mass, especially when combined with a marked reduction in size of the 
abdominal mass during chemotherapy. 
Unlike other workers we found that the residual mass after chemotherapy for 
disseminated pure seminoma could contain viable tumour (17,18). This was found in 4 
of 15 patients with pure seminoma. Motzer et al reported similar results (19). The 
reduction of retroabdominal metastatic tumour after chemotherapy appeared to be of 
value. A relative decrease of more than 70% was always associated with fibrosis in our 
patients. The reduction was significantly less in the group of patients with residual viable 
rumour or mature teratoma. A residual mass >50 mm was associated with mature 
teratoma or viable tumour. Mature teratoma was often found after an increase in 
metastatic mass during chemotherapy. However, even in the smallest residual mass, 
viable tumour cells could be present. Other investigators could not find such a clear 
correlations between radiological findings and histological outcome (20,21). 
Although we operated on a relatively large number of patients after chemotherapy, it is 
unwise to generalise from a small study group. Prospective studies with large numbers 
of patients will give more insight into this important issue. 
It was concluded that the relative reduction in size of metastases in patients on 
chemotherapy and the size of the residual mass after chemotherapy are significantly 
related to histological outcome; the histology of the primary tumor is also of prognostic 
importance. Prospective trials should be undertaken to find out if chemotherapy could 
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be reduced when there is a rapid reduction in tumour volume and no teratomatous 
elements in the primary tumour, and if prolonged chemotherapy might obviate the need 
for surgery in other cases by bringing about complete remission. 
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SUMMARY 
A statistical analysis of prognostic factors in 175 patients with hormonally 
treated disseminated prostatic cancer was done. The prognostic significance of 
performance status (PS), hemoglobin (Hb), alkaline phosphatase (AlkP), and 
testosterone was assessed with a univariate analysis. The authors did not find 
significant prognostic value in age, tumor size or grade, prostatic acid phosphatase, or 
prostate-specific antigen in these patients. In a multivariate logistic model (Cox 
regression), PS, Hb, and AlkP were found useful for dividing patients into prognostic 
groups. The prognosis for high risk patients on standard hormonal treatment was very 
poor. 
The authors concluded that research on prognostic factors is useful and 
permits a division of patients into risk groups that makes choice of treatment more 
accurate. The use of new treatment combinations at the start is appropriate for high 
risk patients with disseminated prostatic cancer. 
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INTRODUCTION 
Since the development of "androgen deprivation" by Huggins, et al., over 45 
years ago, hormonal manipulation has been the best available treatment for patients 
with disseminated prostatic carcinoma (1). The improvements brought about by new 
methods of hormonal deprivation are mainly a better subjective response and 
reduction of side effects. But sofar no important prolongation of survival has been 
observed. Several methods of mechanical or chemical castration have been used, 
especially recently. However the value of chemotherapy is limited, partly by its poor 
effectiveness and its side effects (2,3). New kinds of therapy are therefore needed, 
especially for patients who are refractory to the present ones. 
Extended knowledge regarding prognostic factors is essential for the design of 
future studies. It is important to be able to divide patients into risk groups, so that we 
can select appropriate therapeutic options. On basis of a retrospective study we 
analyze here the value of various prognostic factors in the selection of treatment for 
patients with disseminated prostatic cancer. 
PATIENTS AND METHODS 
Between September 1984 and January 1988, 191 patients entered two trials 
organized by the Dutch South Eastern Urologie Oncology group: 75 patients received 
luteinizing hormone-releasing hormone (LHRH) as a monthly depot (Zoladex, ICI, 
London), and 116 patients underwent orchiectomy with or without administration of 
an anti-androgen (Anandron, Roussel, Paris) (4,5). The results of the two trials were 
similar in hormonal deprivation, and the groups were pooled for analysis of prognostic 
factors. Of the 191 subjects, 16 with advanced, but local, disease were excluded; 175 
patients with bone metastasis (M+, according to the TMN classification model) 
remained. 
Pretreatment factors analyzed for prognosis were age, performance status (PS, 
Karnofsky score), rumor size (T according to the TMN classification, with rectal 
palpation and transrectal ultrasonography), and grade (according to Mostofi, 6). 
Laboratory results included were hemoglobin (Hb; in anaemia Hb < 8.5 mmol/L), 
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alkaline phosphatase (AlkP), prostatic acid phosphatase (PAP), prostate-specific 
antigen (PSA), and testosterone. PSA was determined with the immune-enzymetric 
Tandem-e-psa assay (Hybritech). Testosterone was measured in 75 patients who were 
in a pharmacokinetic clinical trial; 59 with M+ were evaluated. Because the patients 
were treated at different centers, laboratory AlkP and PAP results were standardized 
and classified relative to the upper limit of the normal range. 
A patient was declared to have progression if his area of bone lesion 
involvement (entire body) increased more than 25% or the number of bone lesions 
increased, as compared to the best response. 
Statistical methods: 
Time to progression and survival, calculated from the start of treatment, were 
used as end points in this study. Survival was considered with respect only to death 
related to cancer. To assess the influence of the mentioned above factors, the Kaplan-
Meier method was used for estimation, and the log-rank test was applied for statistical 
testing. In a multivariate analysis using the proportional-hazard model (Cox 
regression), we analyzed the variables simultaneously with a stepwise procedure (on 
level ρ = 0.10) (7). 
RESULTS 
During the period of follow up (mean, 2.3 years), 92 of 175 patients had 
progression on hormonal treatment. Of those 92, 82 died, 68 because of prostatic 
cancer. 
The results of univariate analysis of prognostic factors are shown in Table 1. 
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Factor No. 
2-yr survival Ρ value 
(Kaplan-Meier) (log-rank test) 
Age 
Grade 
PS 
Hb 
AlkP 
PAP 
PSA 
Test 
<60yr 
60-70yr 
70-80yr 
>80yr 
0 
1 
2 
3 
4 
1 
2 
3 
100% 
80-90% 
60-70% 
0-50% 
>8.5 mmol/l 
<8.5 mmol/l 
normal 
-2.5 χ U/l 
more 
normal 
-2.5 χ U/l 
-10.0X U/l 
more 
<100 micrg/l 
100-300 
300-800 
>800 micrg/l 
<300 ng/dl 
>300 ng/dl 
10 
58 
80 
27 
19 
18 
31 
46 
59 
21 
74 
74 
43 
73 
41 
14 
83 
90 
58 
57 
57 
22 
36 
45 
71 
30 
31 
37 
34 
17 
42 
0.34 
0.64 
0.61 
0.48 
0.45 
0.47 
0.47 
0.58 
0.65 
0.69 
0.63 
0.62 
0.72 
0.65 
0.43 
0.51 
0.76 
0.48 
0.76 
0.51 
0.47 
0.74 
0.61 
0.62 
0.55 
0.79 
0.62 
0.48 
0.47 
0.49 
0.74 
0.44 
0.70 
0.17 
0.006 
<0.001 
< 0.001 
0.16 
0.74 
0.024 
TABLE 1 Univariate Analysis of Prognostic Factors 
PS: performance status (Karnofsky score); Hb: hemoglobin; Alk Ρ: alkaline phosphatase; PAP: 
prostatic acid phosphatase; PSA: prostate-specific antigen. 
The values of prognostic factors were the same for time to progression during 
hormonal treatment and for the survival, so only the values for survival are given. Bad 
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PS, anemia, and high AlkP were significantly related to shorter survival. Low 
testosterone concentration at the start of therapy was also associated wit poor 
prognosis. Histologic grade was not significantly related to survival. PAP only showed 
a numerical trend. As for PSA, no significant relation to prognosis could be detected 
in these patients with disseminated prostatic carcinoma, although there was a trend to 
better 2-year survival with lower initial value of the antigen. We could not find a 
relation of age and Τ category at the beginning of therapy to survival. 
After this univariate analysis, we did a multivariate analysis according to the 
Cox-regression model. All the variables (Table 1) were included in a stepwise analysis. 
The results are given in Table 2. 
Factor 
Hb 
AlkP 
PS 
<8.5 mmol/L 
>1.25x upper limit 
<100% 
< 60% 
ß 
0.50 
1.14 
0.85 
0.95 
Ρ value 
0.07 
<0.001 
0.018 
0.022 
TABLE 2. Results of Cox Regression Model 
Hb: hemoglobin; Alk Ρ: alkaline phosphatase; PS: performance status (Kamofsky score) 
PS, Hb, and AlkP were useful for obtaining prognostic groups. The other 
variables did not give additional information for these groups, although for 
testosterone this could be due to the relatively small number of patients (59) in whom 
it was measured. We were able to form three groups (good, moderate, and bad) for 
predicting the duration of survival.(Table 3 and Figure 1). 
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Good 
(η = 64) 
AlkP < 1.25 χ upper normal value 
and PS = 100% 
AlkP < 1.25 χ upper normal value 
and PS = 60-90% 
and no anemia 
Moderate 
(n = 46) 
Not in good or bad group 
Bad 
(η = 5 η 
AlkP > 1.25 χ upper normal value 
and PS < 50% 
AlkP > 1.25 χ upper normal value 
and PS 60-90% 
and anemia 
TABLE 3. Prognostic Groups 
Alk Ρ: alkaline phosphatase; PS: performance status (Karnofsky score). 
Figure 1: prognostic groups 
survival 
years 
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DISCUSSION 
At least 20-30% of patients with disseminated prostatic cancer do not react to 
hormonal treatment, and an equal percentage becomes resistant to the treatment 
within 2 years (8). New treatments are needed for these subgroups of patients. 
Possibilities of new hormonal and cytotoxic treatment were reviewed earlier in this 
journal (9,10,11). To identify patients with a poor prognosis before the start of 
treatment, analysis of factors that influence survival are useful. 
In our study, PS, Hb, AlkP, and testosterone were found to be of prognostic 
significance. The importance of PS and Hb has been reported by Berry et al., but they 
used these factors for hormonally unresponsive prostatic cancer treated with 
chemotherapy (12). The unfavorable influence of high AlkP on survival was 
remarkable and has been established by others (13,14,15). According to Wilson et al., 
a low testosterone concentration at the start of hormonal treatment is an adverse 
prognostic sign (16). PAP is generally accepted as having prognostic significance, but 
we could not find a significant influence of PAP on survival in our patients (17,18). 
PSA is widely accepted as the most important factor for detection of prostatic cancer 
and monitoring of its treatment (19,20). In our patients with disseminated carcinoma, 
PSA did not influence survival significantly, although there was a steady decrease in 
survival with increasing PSA. Comparable results were obtained by Kuriyama, et al. 
(21). Age was not a significant prognostic factor in our study. That result confirmed 
the result of Harrison, but Wilson et al. detected a worse prognosis for patients under 
60 and over 80 (22,23). 
On the basis of our multivariate analysis, we defined three risk groups that 
react differently on hormonal treatment. High-risk patients included those with a 
disseminated prostatic cancer that is so far advanced that it worsens PS, results in 
anemia, and raises AlkP. Those patients should be subject to new kinds of treatment; 
the use of currently accepted standards should be questioned. That is in view of the 
expected early escape from hormonal therapy, which is more likely to occur with their 
more aggressive tumors. It is logical to select this group of patients to examine 
whether early combination of hormone and cytotoxic therapy or radiotherapy is 
superior to hormonal manipulation alone. The aim of the combination is to prevent 
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growth of both hormone-dependent and hormone-independent tumor cells from the 
beginning and to lengthen time to progression and therefore improve survival (24). 
In summary, we conclude that treating patients with disseminated prostatic 
cancer in a general way does not justify the heterogeneity of response to standard 
therapy. By statistical analysis, we established the importance of prognostic factors for 
forming risk groups. Especially for the high risk group, innovative treatment is needed. 
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SUMMARY 
The biochemical markers alkaline phosphatase (Alk Ρ), prostate acid phosphatase 
(PAP), and prostate-specific antigen (PSA) were measured 3-monthly in 61 patients with 
disseminated prostatic cancer who were treated with LHRH analogues. The decrease in 
Alk Ρ and PSA during the first 6 months of treatment was significantly related to a better 
survival. In this follow-up study only PSA was useful for monitoring of prostatic cancer 
during hormonal treatment. Before it was visible on a bone scan, PSA gave an indication 
of tumor progression. PSA might permit omission of routine bone scanning. Consensus 
must be obtained about the cost-saving use of biochemical markers in the treatment of 
disseminated prostatic cancer. With the number of treatment options increasing, objective 
measures are of utmost importance. Biochemical markers can be used for prognosis and 
monitoring of the treatment of patients with disseminated prostatic cancer. 
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INTRODUCTION 
Prostate cancer is one of the major causes of death in older men in western 
countries (1). Hormonal therapy has been used for disseminated prostatic cancer for 
some 50 years and is still the treatment of choice (2). During the last few years, an 
increasing number of new treatment regiments have been studied, in an attempt to 
improve objective and subjective responses and a reduction in side effects. Several 
possible hormonal and cytotoxic treatments have been evaluated, but no spectacular 
improvements in survival have appeared (3-5). 
The design of future studies will require extensive knowledge of prognostic factors 
that will give objective information on the response to treatment and will be helpful in 
monitoring patients with prostatic cancer. For practical and economic reasons, it is useful 
to derive those prognostic factors from laboratory results. Within this context, we studied 
the known factors prostate-specific antigen (PSA), alkaline phosphatase (Alk Ρ), and 
prostate acid phosphatase (PAP), with regard to the prognosis of patients with metastatic 
prostate cancer and the monitoring of their tumors during hormonal treatment. 
PATIENTS AND METHODS 
Between September 1984 and January 1988, 61 patients with newly diagnosed 
metastatic (M+) prostate cancer received luteinizing hormone-releasing hormone 
(LHRH) as a monthly depot (Zoladex, ICI) (6). These patients were part of a 
pharmacokinetic study which was organized by the Dutch South Eastern Urologie 
Oncology group. Pretreatment values of PSA, Alk Ρ, and PAP were measured. During 
the follow-up these values were measured every 3 months. Liver function tests were 
performed to ensure that the Alk Ρ increase was due to bone metastases. Because the 
patients were treated at different centres, Alk Ρ and PAP were standardized and 
classified relative to the upper limit of the normal range. PSA was determined with the 
immune-enzymetric Tandem-e-psa assay (Hybritec, San Diego, Calif., USA) in one 
laboratory. 
A patient was considered to have progression if the area of bone lesion 
involvement (entire body) increased by more than 25% or if the number of bone lesions 
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on bone scintigraphy increased as compared with the best response. 
Statistical Methods 
We used time to progression and survival, both calculated from the start of 
treatment, as end points in this study. Survival was considered with respect only to 
cancer-related death. To assess the utility of the 3 biochemical markersm, we used the 
Kaplan-Meier method for estimation and the log-rank test for statistical testing. Where 
appropriate, a chi-square test was applied. 
RESULTS 
During the follow-up (mean 3 years), 36 of the 61 patients had a progression. Of 
those 36, 31 died, 26 deaths were due to the prostate cancer. 
Six months after the start of hormonal therapy the values of PSA, Alk Ρ, and PAP 
were measured and compared with the pretreatment values. The relation between these 
examinations and progression is shown in table 1. 
η time to progression (mo) 
PSA 
p=0 024 
< 90% decrease 
> 90% decrease 
Alk Ρ 
decrease 
same/increase 
PAP 
decrease 
same/increase 
15 
43 
31 
28 
47 
9 
10 
27 
30 
20 
22 
18 
p=0 70 
p=0 27 
Table 1 relative change after 6 mo of treatment. 
Time to progression and survival during hormonal treatment are equally related to the 
results, so only the values for progression are given. Of the 3 factors only a change in 
PSA showed a significant influence on time to progression, but only if there was a 
dramatic change in PSA (more than a 90% decrease). The absolute values of PSA, Alk 
Ρ, and PAP after 6 months of treatment are shown in table 2. PSA under 10 ng/ml 
appeared to be related to a better prognosis. The clear difference is shown in figure 1. 
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Figure 1 : PSA after 6 months of treatment 
survival 
0,4 
0,2 
— PSA< 10ng/ml + PSA> 10ng/ml 
10 15 20 25 30 35 40 
months 
A relation could also be detected for Alk Ρ; a normal value after 6 months of 
therapy was related to a better prognosis. We could not find significant results for PAP 
on this subject (Table 2). 
PSA < 10 ng/ml 33 
> 10 ng/ml 26 
time to progression 
(mo) 
22.7 
12.5 
p= 0.0002 
survival 
(mo) 
33.2 
18.8 
p= 0.041 
Alk Ρ normal 
abnormal 
33 
26 
21.1 
14.4 
p= 0.0067 
31.0 
19.7 
p= 0.0018 
PAP normal 
abnormal 
37 
20 
19.9 
15.5 
28.2 
19.4 
p= 0.12 p= 0.19 
Table 2: Values after 6 mo of treatment in relation with progression and survival 
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We determined the values at 6 months after treatment as a new baseline for the 
three factors. Changes on this baseline within 3 months before tumor progression was 
seen on the bone scan were compared with the corresponding changes in patients whose 
tumors did not progress. Results are shown in table 3. We can see that only for PSA an 
increase compared with the baseline was significantly related to progression on the 
following bonescan. For Alk Ρ and PAP, only trends are visible. 
-Alk Ρ 
progression 
no progression 
π 
31 
11 
change in 
decrease 
4 (12.9%) 
1 (9.1%) 
biochemical factor 
equal 
15(48 4%) 
8 (72 7%) 
increase 
12 (38 7%) 
2 (18 2%) 
PAP 
p = 0 37 
progression 
no progression 
30 
15 
2 (6.7%) 
2 (13.3%) 
14(46 6%) 
10 (66 7%) 
14(46.7%) 
3 (20 0%) 
PSA 
progression 
no progression 
25 
15 
5 (20 0%) 
7 (46 7%) 
p = 0 07 
20 (80 0%) 
8 (53 3%) 
p= 0 02 
Table 3 Changes from baseline values before progression measured on bone scan or last 
obtained values. 
DISCUSSION 
At least about 25-30% of patients with disseminated prostatic cancer do not react 
to hormonal treatment, and an equal percentage become resistant to the treatment within 
2 years (8). With the use of prognostic parameters we are able to define these high risk 
patients. In a multivariate analysis Soloway determined a group of patients with a bad 
prognosis by using the extent of disease on a bone scan, serum testosterone concentration 
and performance status (10). In a recently published study, we defined a high-risk group 
for tumor progression and a 3-year survival of 0% by using the values of Alk Ρ, 
hemoglobin, and performance status (9). Especially for such a high-risk group innovative 
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treatment is needed. Randomized trials are mandatory in the near future to establish new 
treatment options. Treatment options as early combination of hormonal and cytotoxic 
therapy or radiotherapy may prolong survival for these patients. Within this prospect 
factors that are of value for prognosis and for monitoring patients with advanced 
prostatic cancer during various treatments are increasingly important. The follow-up of 
patients with hormonally treated metastatic prostatic cancer consists of clinical, radiologic, 
and laboratory measurements. Bone scan investigation is still the standard in the follow-
up and determination of progression. As for laboratory results, the three most widely 
investigated and used biochemical factors are PSA, Alk Ρ, and PAP; these are relatively 
inexpensive. In our previous study we examined the prognostic significance of the 
pretreatment values of these three factors and the survival. Only the pretreatment value 
of Alk Ρ was significantly related to shorter survival. Although there was an obvious trend 
between higher PSA or PAP and shorter survival, it was not statistically significant (9). 
Concerning PSA Kuriyama et al. obtained the same results in their original study (12). 
The value of Alk Ρ has been neglected for many years. However, its prognostic value in 
patients with a positive bone scintigram has been established by many investigators (21-
24). In this follow-up study, we found that a significantly longer survival was related to 
normal Alk Ρ after 6 months of treatment. Alk Ρ was not useful in monitoring of the 
cancer. 
PAP has been extensively studied in relation to survival and time to progression. 
The prognostic significance of PAP has been used for many years (17,18). Since the 
introduction of PSA, the value of PAP has lost importance as a prognostic factor, 
especially in metastatic prostatic tumors (13,19,20). In our study, PAP was not of 
prognostic significance with regard to change during treatment, or monitoring of patients 
with metastatic prostatic cancer. 
Important improvement has been made in the detection of PSA by Wang et al 
(11). Extended research has been done on the value of PSA for prognosis. PSA appeared 
to be of more importance for the detection and monitoring of prostatic cancer than as 
a pretreatment prognostic factor (9,12-15). The change in the value of PSA during 
hormonal therapy was of prognostic significance for survival. To obtain a better 
prognosis, a spectacular decrease in PSA is needed. An absolute value of PSA less than 
10 ng/ml after 6 months of treatment was related to a prolonged time to progression and 
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therefore to survival. Cooper et al recently described similar results; the value of PSA 
must be in a normal range (< 10 ng/ml), although this was significant only in a 
quantitative analysis with the use of bone scintigraphy (16). Like others, we established 
the importance of PSA in monitoring hormonal treatment (12-15). In a significant 
number of patients, we saw an increase in PSA before we could see progression on a 
bone scan. Therefore, we believe that it is possible to monitor hormonal treatment with 
PSA and therefore omit the bone scan for routine follow-up examinations. 
We conclude that prognostic measures are of major clinical importance in the 
management of patients with metastatic prostatic cancer. Clinical, pathologic, 
radiographic, and biochemical indicators are available and can be used not only to classify 
patients in prognostic groups, but also to assist in the selection of a therapeutic approach 
adapted to the characteristics of individual patients. With the number of treatment 
options increasing the importance of the availability of several prognostic factors is clear. 
Especially for patients with a poor prognosis innovative therapeutic approaches are 
needed to prolong survival. Therefore an improvement of objective measurements of 
treatment response is mandatory. 
Factors like PSA, Alk Ρ, and PAP are now used in every clinical practice in 
patients with prostatic cancer. They are relatively inexpensive. Taking into account the 
recent reports on the use of these biochemical factors and the results of our own study, 
we aim at reaching a consensus on their value in estimating the prognosis of disseminated 
prostatic cancer and in monitoring the results of its treatment. Before treatment, Alk Ρ 
can be used as a prognostic indicator of time to tumor progression and therefore survival. 
PSA can be used in monitoring results of treatment; routine bone scanning might become 
unnecessary. More side studies in association with prospective randomised therapeutic 
trials dealing with these issues need to be performed before the value of the described 
biochemical markers over other investigations such as bone scan will be fully 
substantiated. Both in Europe (EORTC GU group) and in the United States such studies 
are in progress now. 
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SUMMARY 
Background: Patients with T1G3 bladder cancer have a considerable risk for recurrence 
and\or progressive disease. Until now no consensus has been achieved on the optimal 
treatment. 
Methods: Within the Dutch South Eastern Bladder Cancer Study Group 155 patients 
with a T1G3 bladder tumor were seen between 1983 and 1988. After review of histology 
121 could be evaluated and recurrence-free interval was studied with regard to prognostic 
factors. Prognostic factors such as sex, age, bloodgroup, abnormalities on intravenous 
urography (IVU), pretreatment tumor configuration, number of tumors, number of 
locations involved in the bladder, voided urine cytology, results of the random biopsies, 
and mitotic index were evaluated, using a multivariate analysis with the Cox proportional 
hazard model. 
Results: During the follow-up period 70 (58%) patients had recurrent bladder cancer, 
and of these 30 (43%) had progression into invasive disease. Of the possible prognostic 
factors analyzed, only multiplicity (p=0.03) and the number of locations of the tumors 
(p=0.03) were independent prognostic factors in relation to the risk of recurrence. The 
recurrence free interval was influenced by the therapy. For T1G3 tumors additional 
intravesical immuno-\chemotherapy or radiotherapy after transurethral resection (TUR) 
increased the recurrence-free interval significantly. 
Conclusions: Because most other parameters did not show additional prognostic value, 
the T1G3 tumors can be considered as homogeneous concerning the prognosis. Only 
multiplicity and the number of locations involved added to the prognostic significance of 
patients with these bladder tumors. In addition we advise to give patients with T1G3 
tumors additional treatment after the initial TUR. 
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INTRODUCTION 
The clinical course of superficial bladder tumors (Ta-Tl, Gl-3, Tis) is 
characterized by its unpredictability. Although it is obvious that the strategy of treatment 
differs from muscle-invading bladder cancers, no consensus has been reached about their 
therapy (1). Transurethral resection (TUR) of all visible tumor remains the cornerstone 
of treatment, but the initial TUR is followed by a heterogeneous therapy schedule (1,2). 
Different forms of adjuvant treatment have become available in the last decades. 
Developments in intravesical chemotherapy and immunotherapy have introduced new 
treatment options for superficial bladder tumors and allow to individualize therapy (3-5). 
On the basis of prognostic factors patients with superficial bladder cancer can be divided 
in subgroups (6,7). Subdivision by tumor stage and grade is most important and can play 
a role in the treatment selection, the individualization of therapy, and the development 
of future studies (8,9). 
Patients with T1G3 tumors are at special risk, because of the high recurrence rate 
of these tumors and their special tendency to develop muscle-invasive disease (10,11). 
The incidence of T1G3 transitional-cell carcinoma of the bladder varies from 6 to 23% 
of all superficial bladder tumors, recurrences occur in 50 to 90% of patients and 
progression to muscle-invading disease in 25 to 50% of the patients (6,10,11). Several 
studies discussed the term "superficial" for these T1G3 patients. Abel showed the 
unfavourable outcome of patients with pTl tumors and wanted to reconsider the term 
"superficial" (12). Jakse et al. defined the 40 T1G3 patients they studied as a high-risk 
group and asked for special caution (10). 
Within the Dutch South Eastern Bladder Cancer Study Group we were able to 
evaluate the sofar largest series of T1G3 bladder tumors for analysis of prognostic 
factors, treatment, and recurrence rates. 
PATIENTS AND METHODS 
From 1983 to 1988, 2,075 patients with newly diagnosed bladder tumors were 
registered in the Dutch South Eastern Bladder Cancer Study Group. The group is a 
cooperative organization of 45 urologists (working in 24 hospitals), five radiotherapy 
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centres, and five pathology departments. 155 Patients with T1G3 tumors were registered 
according to the TNM classification and grading according to Mostofi, with a slight 
modification according to Pauwels (13-15). To exclude interindividual variations, one 
pathologist (E.S) reviewed all slides histopathologically. Of 121 patients the specimens 
were sufficient for histological characterization, correctly staged and could therefore be 
included in the study. Of these 104 were men and 17 women, age ranged from 37 to 88 
years (median, 70 years). All patients underwent complete resection of the tumor 
including deep resection of muscle, and random biopsies were taken from 79 patients 
(65%). Carcinoma in situ was found in 19 of 79 biopsy specimens (24%), and dysplasia 
in 16 of 79 (20%). 
Treatment was instituted according to the preference of the members of the study 
group, and given immediately after the histological diagnosis. The patients were treated 
in eight ways, mainly TUR only (48 patients), TUR and radiotherapy (22 patients), and 
TUR and intravesical immunotherapy or chemotherapy (51 patients). In 16 of the 19 Tis 
patients adjuvant treatment was given. Five patients underwent a cystectomy after 
primary diagnosis. The radiotherapy was given as external radiation of 44 Gray on the 
pelvic region and in addition external radiation of 66 Gray as a boost on the bladder 
region. The intravesical therapy consisted of mitomycin-c (30mg in 50cc saline), given 
once a week for one month and thereafter once a month for a total of six months after 
TUR or BCG (BCG-Tice or BCG-R.I.V.M.), given once a week for six consecutive 
weeks. Median follow-up for recurrence and survival was 4 years (range, 3-8 years). 
Bloodgroup, abnormalities on IVU (visible tumor in the bladder and\or dilatation 
of the upper urinary tract), tumor configuration, number of tumors, number of tumor 
locations, cytologic results of voided urine, biopsy results, and mitotic index were analyzed 
as prognostic factors. The bladder was divided into eleven distinct regions, namely the 
trigone, right ureteral orifice, left ureteral orifice, right wall, left wall, anterior wall, 
posterior wall, dome, bladder neck, prostatic urethra and prostate. Malignant cytology 
was defined as an increase of the nuclear-cytoplasmic ratio, hyperchromatosis of the 
nuclei, polymorfic nuclei and cells, and the appearance of papillary structures. The 
mitotic index of the tumor expresses the number of mitotic figures per 10 high power 
(x40) fields of neoplastic tissue. As criteria for counting mitosis we used the 
recommendations of Baak (16). 
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A recurrence was defined as a histologically proven bladder tumor after TURT, 
progression was defined as the development of muscle-invasive disease. 
Statistical methods: recurrence curves were computed with the actuarial method. To test 
the equality of curves for several groups we used Log-rank tests. We explored the 
possibility of intergroup differences in important confounding prognostic variables 
(regarding recurrence) by estimating ß 's in Cox's proportional hazard model. The cut· 
offs for the various variables were taken with allowance of number of patients in order 
to obtain statistical significance. 
RESULTS 
Of the 121 patients with T1G3 bladder tumors, 70 (58%) had recurrent bladder 
cancer during the follow-up period, and 30 of the 70 (43%) showed progression into 
muscle-invasive tumors. During the follow-up period, 41 patients (34%) died, 15 of them 
(36%) from bladder carcinoma. Death due to bladder cancer was not influenced by 
treatment. Of the patients who died of other causes, two were known to have recurrent 
superficial bladder cancer at the time of death. 
Results of a multivariate analysis of pretreatment prognostic factors are given in 
table 1. 
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Prognostic factor 
age 
(year) 
sex 
blood group 
rvu 
tumor 
configuration 
tumor number 
number of 
regions 
cytologic 
results 
biopsy 
mitoses 
(number) 
>70 
<70 
male 
female 
0+ 
other 
normal 
abnormal 
papillary 
solid 
solitary 
multiple 
1 
>1 
malign 
no 
no Tis 
TIS 
<10 
>10 
nurr 
62 
59 
104 
19 
33 
66 
79 
42 
93 
27 
74 
45 
52 
69 
39 
33 
60 
19 
46 
70 
0.15 
0.19 
0.21 
0.02 
0.11 
0.53 
0.54 
0.57 
0.14 
0.10 
p-value 
0.54 
0.57 
0.47 
0.93 
0.72 
0.03 
0.03 
0.10 
0.65 
0.68 
Table 1 Multivariate Analysis of Prognostic Factors 
Of the measures examined, multiplicity (p=0.03) and location of the tumors in 
more than one region (p=0.03) were both independent prognostic factors for time to 
recurrence. Especially in patients with multiple tumors located in different regions of the 
bladder were at risk for recurrence. We did not find additional prognostic significance 
for bloodgroup, abnormalities on IVU, pretreatment tumor configuration, cytologic 
results from voided urine, biopsy results and mitotic index (p>0.05) 
Table 2 compares type of therapy with rates of recurrence and progression. Adjuvant 
treatment prolonged the time to first recurrence significantly (p=0.001) (table 2 and 
figure 1). 
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1 patients 
LIRonly 
UR+intraves 
UR+radioth 
η 
121 
48 
51 
17 
median time 
of first 
recurrence 
(month) 
12 
11 
19 
25 
(p<0.05) 
recurrence 
during 
follow-up 
(%) 
58 
75 
55 
35 
(p<0.05) 
progression of 
recurrences 
(%) 
43 
36 
50 
50 
(n.s.) 
able 2 Treatment and Recurrence, Progression 
.В.: -TUR vs TUR+adjuvant treatment: p<O.05 for median time of first recurrence and recurrence 
during follow-up. 
-TUR+intraves vs TUR+radioth: Not significant (n.s.) for median time of first recurrence and 
recurrence during follow-up. 
¡gure 1 : actuarial risk of recurrent disease 
100 
-"-TUR+adjuvant therapy +TUR-only 
5 6 7 
years of follow-up 
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Patients with TUR only showed a shorter recurrence-free interval than patients 
with TUR plus radiotherapy or TUR plus bladder instillations. No significant difference 
was seen between TUR plus radiotherapy and TUR plus intravesical immunotherapy or 
chemotherapy (p=0.34). We could not find in this study that additional treatment was 
of use in especially multiple cancers. 
Mainly during the first year of follow-up, there was a relatively high actuarial risk 
of recurrence after TUR alone (64%). The incidence of recurrent progressive disease was 
not influenced by treatment type (p=0.74). It must be noticed that the three treatment 
arms were completely matched with regard to the other prognostic factors. 
DISCUSSION 
The prognosis of superficial bladder cancer mainly depends on the risk of 
recurrent disease. In the majority the recurrences will remain superficial, but about 10 
to 15 per cent of the patients will show progression into muscle-invasive disease (6). This 
cancer has an overall recurrence rate of 50-70 %, while progression into muscle invasive 
disease occurs in 2-40 % (6). 
From several reports on prognostic factor analysis we noticed the clear 
heterogeneity of the superficial tumors (6,7). It must therefore be questioned why 
superficial bladder tumors have been classified mainly as a single group, and consequently 
treatment protocols have been developed and results have been evaluated on that basis 
(1,3). The most significant prognostic factors in superficial bladder cancer are tumor stage 
and grade (8,9). Combining these factors a subgroup of T1G3 tumors can be defined. 
Although considered superficial, this tumor is associated with a high risk of recurrence, 
and progression, and therefore death. However, the number of T1G3 patients, as a 
subdivision of superficial bladder tumors, studied in the literature is small (6,7). Several 
studies underline the high tendency to develop recurrent disease for these tumors (10,11). 
Although T1G3 transitional-cell carcinomas of the bladder are known to have a worse 
prognosis than other superficial bladder tumors, consensus about their treatment is 
lacking. Treatment regimens range from TUR only to radical cystectomy in these tumors. 
We were able to study the largest number of patients with T1G3 tumors published 
sofar. From our study of 121 histologically reviewed T1G3 superficial bladder tumors it 
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became evident that adjuvant treatment decreases recurrence rate and increases the 
recurrence-free interval significantly. The prophylactic use of adjuvant intravesical 
immunotherapy or chemotherapy has been stated to improve treatment results (4,5). Like 
others we believe that this kind of adjuvant treatment should not be given for every 
superficial bladder tumor, but it is advisable for T1G3 tumors (1,10,11). Radiotherapy is 
not widely used for superficial bladder tumors. Although this study was not done in a 
randomized prospective way, the results indicate the beneficial effect of radiotherapy on 
recurrence-free interval, as has been stated by others (17,18). Patients with T1G3 bladder 
tumors need to be treated with special caution. Additive treatment is demanded. A more 
agressive approach such as cystectomy may be necessary in the long term, especially in 
patients with a good life expectancy. However, the decision on this radical option may 
be delayed by intravesical instillations after the initial TUR. Herr et al. concluded in a 
well documented randomized study that in high-risk patients intravesical BCG can delay 
disease progression, prolong the period of bladder preservation, and increase the overall 
survival (19). 
Other factors that showed to be of importance were multiplicity of tumors, 
ureteral obstruction, abnormality in random biopsy and cytology results (7,20-22). In our 
study, factors such as bloodgroup, abnormalities on IVU, tumor configuration, results of 
cytology and random biopsy, and mitotic index did not show additional prognostic 
significance. In our opinion this is because our patients were homogeneous for stage and 
grade, which are superior indicators for prognosis and could have masked the less 
important prognostic value of the other characteristics. Only multiplicity and tumor 
location in different regions of the bladder were independent prognostic factors. With the 
use of the multivariate analysis only factors that give additional prognostic significance 
are of value. This may be the reason why our results differ from those of others who 
studied all different superficial bladder tumor categories. The result of this study that 
especially patients with multiple tumors located in different regions of the bladder were 
at risk for recurrence may underline the hypothesis that these patients have diffuse 
premalignant or malignant changes of the bladder, which are not visible at the time of 
the initial TURT. This statement could be analyzed with the use of flowcytometry, which 
showed aneuploid stemcells of normal-appearing mucosa in patients with bladder cancer 
(23). One would expect that especially patients with multiple tumors benefit from the 
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additional treatment. However, in this study we were not able to confirm this. 
More sophisticated techniques such as flowcytometry, karyometry, and tumor 
associated antigen expression have been studied recently, but are not yet of clear 
prognostic value for the daily clinical practice (24-26). They may make it possible to 
subdivide patients with superficial tumors into individual prognostic categories. 
In conclusion, from the results of this study we must advise to give patients with 
T1G3 bladder tumors additional treatment after the initial TURT. Because of the high 
recurrence and progression rate, the term "superficial" should be reconsidered or used 
with caution, with consequences for treatment decision. Patients with T1G3 tumors must 
be classified and categorized separately. To evaluate these T1G3 tumors together with 
other superficial tumors does not justify the heterogeneity of these tumors with regard 
to the risk for recurrence and progression. Additional treatment, especially intravesical 
immunotherapy and chemotherapy, is advisable to prolong the recurrence-free interval 
and to improve the survival of patients with T1G3 bladder tumors. Association with bad 
risk factors, such as multiplicity and location of the tumor(s) in different regions of the 
bladder, might necessitate a more agressive treatment like cystectomy, especially in 
patients with a good life expectancy. In developing future treatment protocols the 
heterogeneity of the "superficial" bladder tumors must be considered. In particular the 
stage, histologic grade, multiplicity, and the number of locations in the bladder of 
superficial tumors must play a role in study design. In these studies the optimal treatment 
for high risk superficial bladder tumors has to be elucidated in prospective randomized 
protocols, which are now in progress in Europe (EORTC GU group) and in the United 
States. 
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SUMMARY 
In a prospective randomized study 387 patients with pT,-pT, papillary carcinoma 
superficial bladder cancer received, after transurethral resection (TUR), intravesical 
instillations with immuno- or chemotherapy. A simultaneous computerized analysis of 
factors predicting recurrence-free interval was performed. All these patients had negative 
random biopsies. Median follow-up was 27 months (range 12-56 months). During the 
follow-up period 37.2% of the patients had recurrence and eight patients (2.2%) had 
progression into muscle invasive disease. 
Pretreatment factors analyzed for recurrence were gender, age, history (primary 
or recurrent disease), location of tumour, number of tumours, pT-stage and grade. After 
an univariate analysis the number of tumours and location of the tumour in the bladder 
appeared to be of significant influence on recurrence-free interval. Location of at least 
one of the tumours in the prostatic urethra, bladder neck, posterior wall, and trigone area 
was significantly related with a shorter recurrence-free interval. We defined these areas 
as high risk. Tumour stage showed borderline significance. By using multivariate methods 
to assess the relative importance of these factors, location of tumour in the high risk 
region was especially related with a short recurrence-free interval. Only multiplicity added 
to the prognosis for recurrence. Neither gender, age, history of recurrent disease, size of 
the largest tumour, tumour stage or grade, gave additional information about risk for 
recurrence. 
We conclude that prognostic factor analysis, as an auxiliary study of trials of 
patients treated for superficial bladder tumours is mandatory. The prognostic factors 
related to recurrence-free interval found in this study, e.g. location of the tumour and 
multiplicity, may be helpful in the stratification neccessary for current protocol design. 
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INTRODUCTION 
Bladder cancer is the third most prevalent malignant disease among male patients 
and the tenth among female patients in the western world (Feldman, 1986). 
Approximately 90% of the bladder tumours are transitional cell carcinomas, and 85% are 
pT. and pT, stages (Silverberg and Lubera, 1987, Soloway, 1989). The disease affects the 
whole urothelium, and is probably caused by certain genetic characteristics of the patient 
or by the toxic effects of the urine on the bladder. Consequently, recurrences after 
resection of the primary tumour are common, making bladder cancer probably the most 
frequently diagnosed tumour in man (Feldman et al., 1986). These features are at the 
rationale for the intravesical therapy. Topical application of chemo- or immunotherapy 
allows contact with tumour-bearing mucosa and consequently may control existing 
tumours and reduce tumour recurrences (Herr et al., 1987, Soloway, 1989, Kurth et al., 
1989). On the other hand we know that not all superficial bladder tumours react similarly 
to this treatment, because of the varying degree of response to the topical agents (Herr 
et al., 1989). Therefore it is advisable to individualize the therapy for patients with 
superficial bladder cancer. Research on prognostic factors may help us to divide these 
patients into groups who will probably respond to therapy and those who will not. This 
subdivision is also important for the design of future studies of treatment, especially with 
respect to the inclusion criteria, follow-up regimens, and for the development of new 
treatment options, with the aim of improving the prognosis. This is why we performed 
an auxiliary study on the prognostic factor analysis of this treatment trial, in order to find 
parameters which are related to chance on recurrence during the follow-up. 
PATIENTS AND METHODS 
Between April 1987 and December 1990, 469 patients with primary or recurrent 
resectable pT,-pT, papillary carcinoma or primary carcinoma in situ (CIS) of the urinary 
bladder, entered the trial which was organized by the Dutch South-Eastem Urological 
Collaborative Group. Patients were recruited from 27 different urologie centers. The trial 
is a comparative prospective randomised study of intravesical instillation of three drugs, 
namely mitomycin-C, BCG-Tice, and BCG-RIVM. The drug was administered after a 
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complete transurethral resection of all visible tumours (TURT), including deep resection 
of bladder wall muscle. 
Before the tumour resection, random biopsies of normal looking mucosa were 
taken. Also every area, pale red or hypervascularized, suspected for CIS was biopsied 
seperately. 82 patients with primary CIS or CIS in the random biopsies were excluded 
from this analysis. All histopathologic slides were reviewed for stage and grade by a 
referee pathologist. 
Intravesical therapy with mitomycin-C (30mg in 50ml saline) was given once a 
week for one month and thereafter, once a month for a total of six months after TURT. 
BCG (BCG-Tice or BCG-RIVM) was given once a week for six consecutive weeks. The 
choice of therapy was made by means of a restricted randomization. After completing 
the therapy, control cystoscopy was performed every three months during the first, second 
and third year. 
Pretreatment factors analyzed for prognosis were: gender, age, history (primary 
or recurrent disease), number of tumours, location of tumour, pT-stage (according to the 
TMN (IUCC.1987 classification) and grade (according to Koss, 1973). The bladder was 
divided into eleven distinct areas, namely the trigone, right ureteral orifice, left ureteral 
orifice, right wall, left wall, anterior wall, posterior wall, dome, bladder neck, prostatic 
urethra and prostate (figure 1). Location of a tumour in one or more of these areas was 
used for the assessment of the risk for tumour recurrence. 
Time to recurrence was calculated from the beginning of the treatment. Disease-
free interval was defined as time interval between the initial TURT and the date of the 
first positive biopsy. The only endpoint used to assess the prognostic factors was the time 
until the first recurrence, i.e. the duration of the recurrence-free interval. Patients with 
no recurrence were analyzed until their last control cystoscopy. 
Statistical methods: 
The effects of the potential prognostic factors (co-variates) were analyzed after 
stratification for treatment. This could be done because no strongly significant differences 
in recurrence rate and progression to muscle invasive disease was observed among the 
three treatment arms and because there was a complete match for the prognostic factors. 
Distribution functions of time to first recurrence were estimated by the method of 
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Kaplan-Meier. First, an univariate analysis for each factor was performed with the use 
of the Wilcoxon-Gehan test, secondly we analyzed the factors simultaneously with the 
stepwise forward selection procedure based on a model-free multivariate logrank test. 
RESULTS 
Of the 387 patients with pT.-pT, superficial bladder cancer and negative random 
biopsies, 371 had sufficient follow-up data. The median age of the patients was 65 years 
(range 31 to 89 years). 310 patients were male, 61 were female. The median time of 
follow-up was 27 months (range 12-56 months). During the follow-up period 138 (37.2%) 
patients had a recurrence. The percentage of recurrence-free patients according to the 
years of follow-up are shown in figure 1. 25% of the patients showed a recurrence within 
41 weeks. 
Figure 1 : overall recurrence-free interval 
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In eight patients (2.2%), the recurrent tumour was muscle-invasive. The factors, that were 
dichotomized for the risk for recurrence, are shown in Table 1. The categories 1 and 2 
stand for a better or worse prognosis respectively. 
FACTOR CATEGORY I CATEGORY II 
gender male female 
age < 65 years > 65 years 
history primary recurrent 
multiplicity solitair multiple 
location other high risk region 
size largest tumour < 2.0 cm > 2.0 cm 
tumourstage pT. pT, 
grade G,,G2 G, 
TABLE 1 
Gender and age: We did not obtain a prognostic significance for gender (p=0.35) or age 
(p=0.10, cut-off point 65 years). 
History of recurrence: Because patients with recurrent disease (84 patients) entered the 
study, we investigated the history of the disease for prognosis. Recurrent disease at entry 
of the study was of borderline significance for a shorter recurrence-free interval (p=0.12). 
Size of the tumour: Patients were divided into two categories according to size of the 
tumour. Patients with small tumours (<2.0 cm diameter) did not have a significantly 
higher risk for recurrence as compared with patients with large tumours (>2.0 cm 
diameter) (p=0.49). 
Multiplicity: The number of tumours resected at presentation was highly significant as a 
prognostic factor in relation to the recurrence-free interval (p=0.0001). Solitary tumours 
were more likely not to recur during the follow-up period. 
Location of the tumour(s): Because the design of the study included the exact description 
of the location of the tumour in the different areas (figure 2), we were able to analyze 
the prognostic impact of the tumour location. In this study, the presence of at least one 
tumour in the bladder neck, prostatic urethra or the posterior wall (p=0.0001. p=0.0004 
and ρ=0.0008 respectively), was related to a shorter recurrence-free interval. Tumor in 
the trigone also proved to be of prognostic significance (p—0.02). These areas are 
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marked in figure 2. 
FIGURE 2: high risk regions of the bladder 
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Tumour stage and grade: The histologic evaluation of the tumour, by a referee 
pathologist was not a very important prognostic factor in our study. pT, tumours, as 
compared with pT. tumours, are slightly more frequent (p=0.07), and associated with a 
shorter recurrence-free interval. Grade proved to be of no prognostic significance at all 
(p=0.89). 
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Table 2 summarizes the results of the univariate prognostic factor analysis. 
p-value 
FACTOR univariate stepwise 
location .0001 .0001 
multiplicity .0001 .002 
tumourstage .07 .11 
grade .89 .24 
history .12 .58 
size largest tumour .49 .51 
gender .35 .14 
age .10 .05 
TABLE 2 
Because different prognostic factors may be interdependent, a study must also consist of 
a multivariate analysis, in order to define independent prognostic factors. In our stepwise 
multivariate analysis, the most important prognostic factor appeared to be the location 
of the tumour (p=0.0001). Of all the other factors, which were subsequently evaluated 
for additional information for the risk for recurrence, only the multiplicity was of 
additional prognostic relevance (p=0.002). The other factors were not independent, so 
no additional information was obtained by using them for the prognosis of the 
recurrence-free interval (p>0.05). 
With the use of the two prognostic factors, location of the tumour and multiplicity 
we were able to form risk groups. Solitary tumours located in the low-risk region showed 
a 12 months recurrence-free interval of 88% as compared with 55% of multiple tumors 
located in the high-risk region. The results are shown in table 3. 
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recurrence-free interval (%) 
6 months 12 months 24 months 
LOCATION 
low-risk 
high-risk 
NUMBER 
OF TUMOURS 
1 
2 
> 2 
1 
2 
>2 
η 
9Θ 
22 
18 
93 
44 
94 
97 
82 
83 
83 
93 
71 
88 
72 
61 
71 
66 
55 
83 
66 
49 
53 
59 
43 
TABLE 3 
Table 4 shows the percentages of recurrent disease for the different factors and 
the time to first recurrence. Estimations are given for the period (days) after the initial 
TURT in which 25% of the patients showed recurrence in a follow-up cystoscopy (R25). 
Furthermore, figures are provided for the different categories of the estimated proportion 
of patients who are free of disease after one and two years respectively. We wish to 
emphasize that when considering the location of the tumours, the R25 values are 
strikingly different for the high risk and other regions respectively. Similarly, when 
considering multiplicity, the criteria of solitary and multiple tumours give significantly 
different R25 values. 
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FACTOR η R25 (days) proportion disease free 
1-year 2-year 
location 
other 
high risk 
multiplicity 
solitary 
multiple 
tumour stage 
PT. 
ρτ, 
grade Gi.G2 
gender male 
female 
age < 65 years 
> 65 years 
history primary 
recurrent 
size largest tumour 
< 2.0 cm 
> 2.0 cm 
TABLE 4 
DISCUSSION 
A suitable spectrum of incisive prognostic factors is an important tool in clinical 
oncology. Consequently, one is striving to exploit fully those which are known and to 
continue searching for new ones. We know that suitable prognostic factors are helpfull 
in achieving the best treatment regimen in the subsets of patients for which they are 
meaningful. Prognostic factors also, are helpful in the basic understanding of tumour 
biology and the design of treatment protocols. No clinical trial studying potential 
treatment options can do without a prognostic factor analysis. 
138 758 
233 225 
191 544 
178 202 
246 304 
125 274 
300 290 
71 269 
310 285 
61 274 
185 274 
186 363 
287 304 
84 253 
133 277 
211 304 
0.82 0.76 
0.64 0.51 
0.80 0.70 
0.60 0.50 
0.73 0.64 
0.65 0.52 
0.71 0.61 
0.68 0.58 
0.70 0.62 
0.71 0.50 
0.66 0.57 
0.75 0.64 
0.72 0.62 
0.65 0.53 
0.71 0.64 
0.72 0.58 
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In this study we found important prognostic factors, relative to recurrence-free 
interval, tumour location and multiplicity. Tumours located in one of the high risk 
regions, namely the bladder neck, prostatic urethra, the posterior wall, the trigone and 
dome, were, after complete TURT, very likely to recur. This point is also mentioned in 
the report of the British Medical Research Council (UK) subgroup on superficial bladder 
cancer (Parmar et al., 1989). They performed a follow-up study of a prognostic factors 
analysis and found that the resection of tumours located in the posterior wall of the 
bladder, implied a high risk of recurrence. In the study of Parmar and ours it is 
concluded that certain locations of the tumour in the bladder exhibit particularly high 
recurrence frequencies. Tumours that arise in these regions should be followed with 
particular care. It is as yet not known why tumours located in these high risk areas so 
frequently recur. A possible mechanism might be the contact time with the bladder 
mucosa and concentration of the intravesical solution in the different regions. Continuous 
fresh urine is produced by both ureters, consequently rinsing the neighbouring regions 
(trigone, posterior wall) and preventing the contact of the tumour with the agent 
installed. The prostatic urethra is normally not in contact with intravesical fluid due to 
the closed bladder neck. However, the exact role of the instillation schedule and its 
influence on the recurrence of tumours at these high risk locations in the bladder is as 
yet unknown and should recieve priority in future studies. 
In many investigations the number of tumours at presentation was found to be of 
importance for prognosis. Parmar and associates stated that the number of tumours 
found, and the cystoscopy findings performed three months after the initial tumour TUR, 
were functionally related to the freqency of recurrence (Parmar et al., 1989). Using these 
two parameters they established relevant prognostic groups of patients, each with a 
particular appropriate follow-up procedure. Dalesio et al.(1983) found, in an auxilliary 
study on trials of treatment in superficial bladder cancer performed by the EORTC, that 
the number of tumours initially resected tumours was a factor influencing recurrence. A 
similar conclusion had been reached in a large series of 761 patients by Koch et al.(1986). 
The National Bladder Cancer Collaborative Group A (NBCCA), also obtained 
comparable results (NBCCA, 1977). 
Tumour stage and grade have been widely accepted as prognosticators for the 
recurrence of tumours (Lutzeyer et al, 1982, Narayama et al, 1983). In groups of patients 
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with superficial bladder cancer, treated with intravesical instillations of chemo- or 
immunotherapy, the influence of stage and grade may be less. This treatment may alter 
the biological behavior of the tumour, especially those at risk for recurrence and 
progression, and may thus influence prognosis. It is therefore advisable to compare the 
results of prognostic factor analyses of different studies, only if the treatment mode is 
identical (e.g. intravesical instillations). In a study of Torrence et al.(1988), who 
investigated patients treated with intravesical Bacillus Calmette-Guerin, the tumour stage 
was of little prognostic significance. We reached the same conclusion in this study in 
which tumour stage was borderline significant for prognosis. Also Parmar et al.(1989) 
assigned small additional value to tumour stage and grade, as compared with the other 
more important factors in a multivariate analysis. They mentioned an important 
disadvantage of histologic typing of bladder tumours, namely the inter-individual variation 
between the local and referee pathologist, which may be appreciable and consequently 
decreases the importance of grade and tumour category in a multivariate analysis. 
Therefore, referee pathology results are essential for the design of a study on treatment 
modalities. Although all slides in our study were histologically reviewed by one 
pathologist, the tumour stage and grade were still of little prognostic importance. 
In our analysis, history of recurrence at entry, showed only an indication, albeit not 
significant, for a higher probability of future recurrences. In the study of Dalesio et 
al.(1983), recurrence rate before entry into the study was a good predictor of prognosis. 
Also Parmar et al.(1989) found a strong correlation between the recurrence of tumour 
with the findings at the 3-months cystoscopy. They used these findings as a substitute for 
a previous recurrence rate. 
The other factors examined in this study, age, gender and size of the tumour, did 
not show prognostic significance. However, they should be included in a multivariate 
analysis because the groups formed with a prognostic impact, will then be stratified for 
these factors. Consequently, the results in such a study, obtained with the model-free 
logrank test, can be adequately used for prognosis. In this way, it is possible to define 
certain risk groups. Knowing factors such as multiplicity and location of the tumour(s), 
we may be able to advise on treatment and follow-up strategies. In patients with 
superficial bladder tumours treated with intravesical instillations, solitary tumours located, 
for example, in the anterior wall of the bladder, may be followed with less frequent 
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cystoscopies, because of the good prognosis. On the other hand, multiple tumours 
located, for example, in the posterior wall of the bladder, should be followed more 
closely, and may be treated with more intensive intravesical instillation therapies. 
Notwithstanding these positive findings, we still need to be more accurate in our 
estimation of the prognosis of a patient, and therefore it remains imperative to search 
for other additional parameters. More sophisticated techniques such as flow cytometry 
and tumour-antigen expression have been studied recently, but are not yet part of daily 
clinical practice, in spite of their value, for lack of neccesary équipement (Murphy et al., 
1986, Blomjous et al., 1988, Falor and Ward-Skinner, 1988, Blasco et al, 1988). With 
karyometric analysis, these examinations might yield additional information about the 
likelihood of recurrence, choice of treatment, and survival (van de Poel et al., 1991). 
In conclusion, with the use of a prognostic factor analysis, especially the 
multivariate analysis, we are able to define risk factors for tumour recurrence in patients 
with superficial bladder cancer, treated with immuno- or chemotherapy. In our auxiliary 
study of one trial involving 371 patients with pT,-pT, superficial bladder cancer, the 
location of the tumour in one of the high risk regions and the multiplicity are defined as 
important prognostic factors relative to the recurrence-free interval. These factors can 
be used for the appropriate choice of treatment and the determination of follow-up 
schedules. 
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SUMMARY 
The variation in tumor cell differentiation within one renal cell carcinoma, 
also termed tumor heterogeneity, renders visual tumor grading of these carcinomas 
difficult. Karyometric analysis enables analysis nuclear characteristics of multiple 
tumor areas. Hence, karyometric analysis can be used to quantify tumor heterogeneity 
and thus may aid in a more objective grading of renal cell carcinoma. 
Of 121 patients with renal cell carcinoma (RCC) (tumors UICC stages: 1 [5 
cases], 2 [23 cases], 3 [33 cases], and 4 [60 cases]) clinical, flowcytometric, and 
karyometric features were studied to obtain routinely applicable prognostic factors. 
Only with karyometry several parts of the tumor were analyzed, to obtain a measure 
of tumor heterogeneity. 
The Cox univariate regression analysis showed correlation of several clinical 
and karyometric characteristics with survival. Flowcytometry did not correlate with 
survival, but this was probably due to the fact that only one sample of each tumor was 
investigated. Of the clinical characteristics TNM, tumor size, weight reduction and 
performance status were significantly related with survival. The karyometric features, 
especially those measurements associated with tumor heterogeneity (e.g. differences in 
chromatin texture) were of value in predicting prognosis. 
In the Cox multivariate regression analysis the Robson and TJICC-stages 
proved to be the most powerful predictors of survival (P< 0.0001). Of the clinical 
features, weight reduction and performance score were the only characteristics 
offering additional information to tumor stage (P< 0.0001). From the karyometric 
analysis quantification of anisokaryosis in the tumor at time of diagnosis offered 
additional prognostic information. Moreover, the differences of karyometric features 
within the tumor presumably associated with tumor heterogeneity correlated with 
survival. Using the features from the multivariate analysis, prognostic groups could be 
defined. 
We conclude that karyometric analysis offers a useful means for quantifying 
tumor heterogeneity. Multivariate Cox analysis revealed additional value of a grading 
system based on karyometric analysis to tumor stage. Karyometric analysis can be a 
useful tool for stratification of patients populations. 
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INTRODUCTION 
Renal cell carcinoma (RCC) accounts for 3 percent of all malignancies and 
the 5-years survival rate is 30 to 60% (1). The tumor is characterized by its 
unpredictable clinical course and only limited effective treatment modalities are 
available. Attempts have been made to classify the patients according to prognostic 
features. The staging system initiated by Flocks and Kadesky and popularized by 
Robson and associates is based on the extent of the tumor and correlates with survival 
(2,3). Another widely used staging model is the TNM system of the American Joint 
Committee for cancer staging which classifies the tumor according to the anatomical 
extent of disease (4). This has been the basis of the staging by the International Union 
against Cancer (5). However, within subgroups of patients as defined by these 
classification models, the clinical course of RCC is still diverse. 
No important improvement in the survival of patients with RCC has been 
achieved during the last decades. Surgery remains the cornerstone of treatment and 
the only way to cure the patient. For patients with advanced disease an increasing 
number of treatment options exists. New treatment modalities like immuno- and 
chemotherapy are under investigation. They have been developed in an attempt to 
improve survival (6,7). Because of considerable side-effects of the, mostly palliative 
drugs the indication for administration must be carefully considered, and only given to 
those patients who may benefit from the treatment. Individualization in the 
management of RCC is therefore of utmost importance and further research for 
prognostic factors is mandatory. 
For several tumors, grading offers prognostic information. Considering the 
extensive tumor heterogeneity in renal cell carcinoma (8) we sought to develop an 
objective grading system analyzing several parts of the tumor. Karyometry is used to 
quantify nuclear features and offers an objective measure of tumor phenotypic 
characteristics. Since heterogeneity will probably result in nuclear differences in light 
microscopy, comparison of the karyometric feature values of different areas within the 
tumor can be an objective measure of tumor heterogeneity. 
In order to obtain the best possible insight in the prognosis of the individual 
patient with RCC, we performed a statistical analysis of the most important clinical, 
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karyometric and flowcytometric features. 
MATERIAL AND METHODS 
Material 
Data were obtained of 121 patients (77 men; 44 women) with a RCC treated 
between 1983 and 1990 with tumor nephrectomy. The patient age ranged from 32 to 
100 years (median 67 years). The median follow up was 21 months (range 4 - 133 
months). 
All the patients could be classified according to the TNM(V)-model and 
staged according to the Robson and the International Union against Cancer (UICC) 
classification models (3,5). 
For patients with metastatic disease several adjuvant treatments were given. 
In 65 M„ patients one or more forms of immuno- and/or chemotherapy were given 
(IFNalpha + IFNgamma: n=58, IFNalpha: n=5, vinblastin: n = l , IL2 + IFNalpha: 
n=l) . In 7 patients palliative radiotherapy was given after the tumor nephrectomy. At 
the time of diagnosis of the primary tumor these additional treatments did not 
improve survival significantly (log-rank test P>0.05). Hence, all 121 patients could be 
grouped and analyzed for prognostic factors irrespective of the additional treatment 
given after tumor nephrectomy. 
Clinical features 
Various clinical characteristics of the patients, in earlier studies found to be 
associated with the outcome of the disease, were recorded for subsequent analysis. 
Besides patient age and gender, these included variables used for the classification 
models like pathologic stage, haematogeneous and lymphogeneous metastases, venal 
invasion of the tumor and tumor size. Moreover, general indicators of the patients 
physical condition were documented like performance status (Karnofsky score), 
history of weight reduction, and serum haemoglobin concentration at time of 
diagnosis. 
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Karyometry features 
All paraffin-embedded archival material for each patient was reviewed by one 
pathologist (H.S.). Morphologically different tumor areas were marked for further 
karyometric analysis. The selection of areas was based on differences in histology 
(papillary and non-papillary) or cytology (clear, granular, and spindle cell). 
Karyometric analysis consisted of nuclear morphometry, densitometry, and chromatin 
pattern analysis with a PC-based image analysis system (VFG-framegrabber board, 
Imaging Technology, Woburn, MA) in a Compaq 386s personal computer). Image 
handling and analysis software was written in TIM (TEA, Dordrecht). For analysis, 4 
Mm thick paraffin-embedded sections were deparaffinized and Feulgen-Schiff stained 
as room temperature. Within the marked areas nuclei in 50 randomly chosen images 
were analyzed with a lOOx objective. After shading correction and image filtering a 
local segmentation procedure was performed based on the grey-value histogram in the 
subimage. Of each nucleus in the recorded images a panel of karyometric features 
was measured (Table 1). 
TABLE 1 
- morphometry 
+ AREA (nuclear profile area) 
+ PERI (nuclear profile perimeter) 
+ FELL (elongation factor) 
+ FPE (nuclear roundness factor) 
+ MAXD (maximal nuclear diameter) 
+ Freeman chain code derived shape factors: 
- BEN/NMAC/PASS/DIS/THRES 
- densitometry 
+ OD (optical density) 
+ IOD (integrated optical density) 
+ OD CV (coeff. of var. of OD) 
- texture analysis 
+ analysis of grey values in maximal diameter axis 
+ Markovian features of co-occurrence matrix: 
- entropy 
- difference moment 
- inverse difference moment 
• rotation moment 
- inverse rotation moment 
+ granulometry (chromatin clots analysis) 
Table 1. Karyometric features. 
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At least 100 tumor nuclei were measured per tumor area. A sequence of 200 
images could be analyzed in 5 hours. Of the analyzed nuclei data and images were 
recorded, thus enabling manual rejection of out-of-focus or faulty segmented objects 
after the measurement by the operator. For each sample the 2c Deviation Index 
(2cDI) and 5c Exceeding Rate (5cER) were calculated (9). 
Since in all tumors morphologically different tumor areas were marked by the 
pathologist, a measure of heterogeneity could be calculated as follows. In all tumors 
for every nuclear feature the tumor area with the highest and lowest value and their 
differences were determined. We also analyzed whether karyometric analysis of tumor 
areas marked by the pathologist was different from at random measurements in the 
tumor. Hence, besides data of the different tumor areas all values of the tumor areas 
were merged and median and difference of 15* and 85m percentiles were calculated to 
obtain a subpopulation independent measure of tumor heterogeneity. 
The karyometric measurements were tested for inter-individual reproducibility 
among three technicians. For this purpose we have chosen randomly 28 out of the 121 
RCC patients. Three technicians performed independently karyometric measurements 
of nuclei in the marked tumor areas. The measured feature values were analyzed for 
their inter-observer agreement using a two-way ANOVA. 
Flowcytometric features 
After tumor nephrectomy, a sample of approximately 2 cm3 was cut from the 
tumor and immediately mechanically or enzymatically processed to tumor suspension. 
It should be noticed that due to this sampling method, the tumor parts used for 
flowcytometric analysis were not identical to the areas selected for karyometric 
analysis. Of the 121 patients, material of 71 patients could be obtained and 
mechanically processed to tumor cell suspensions and fixed in 70% ethanol. 
Propidium iodide staining was applied and chicken red blood cells were used as 
external reference. Several features of the DNA-histogram were calculated: DNA 
index of G0G,-peaks and percentages of cells in different areas of histogram (G0G„ 
GjM, and S-phase). 
114 
Statistical methods 
The time from treatment to death was studied using survival analysis. The 
Kaplan-Meier method was used to estimate the survival function in a group. 
Differences of survival functions between groups were tested for statistical significance 
using log-rank test and Wilcoxon test. The 3-years survival rates with 95% confidence 
intervals were calculated using the Kaplan-Meier method. Cox univariate and 
multivariate regression analyses (i.e. proportional hazard model) were performed to 
estimate the influence of the clinical, karyometric, and flowcytometric features on the 
survival time. Both forward and backward stepwise-selection procedures were used to 
find the best model in predicting the survival time. The stepwise-selection procedure 
was performed in two parts. In part I, the selection was used to find all clinical 
features to define either the best or an equivalent model. The Bonferroni correction 
was used for model entry of a variable. The same procedure was also performed on 
the karyometric feature group. In part II the selection procedure was performed on 
the features from the two feature groups selected in the previous step. 
To obtain a prognostic score (RCC-score: good, intermediate, and poor 
prognosis) based on the selected features in the multivariate analysis, the linear part 
of the best multivariate model (XBeta) from the selection procedure was used. The 
levels of the RCC-score were arbitrarily chosen from jumps in the XBeta values of the 
present patients group. 
RESULTS 
Clinical features 
During the follow-up period 68 (56%) patients died from RCC. The overall 3-
years survival was 48%. The Kaplan-Meier estimators for survival for both Robson 
and UICC classification models in our patients are shown in figure 1 and 2 
respectively. 
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Figure 2. Survival by UlCC-stage. 
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The differences between the 3-years survival percentages of the stages is 
presented in Table 2. 
TABLE 2 
Robson stage 
A 
В 
С 
D 
UICC stage 
1 
2 
3 
4 
η 
20 
14 
32 
55 
5 
23 
33 
60 
3-yrs 
survival 
0.83 
0.77 
0.53 
0.27 
0.67 
0.82 
0.59 
0.29 
LCL U 
0.60-1.00 
0.55-1.00 
0.35 - 0.71 
0.15-0.39 
0.13-1.00 
0.67-1.00 
0.41 - 0.76 
0.17-0.41 
Table 2. Three-years survival values for different stages in UICC and Robson stages. 
Several clinical features appeared to be related with survival. Of the 
pathological features an increase in T, M, or N stage was significantly correlated with 
a shorter survival (ƒ*< 0.005, Cox regression analysis). The presence of venal invasion 
(V), patient age and sex, a low serum haemoglobin concentration at time of diagnosis, 
and the histological tumor type, however, were not significantly related with a shorter 
survival (P>0.10, Cox regression analysis). Other clinical characteristics that predicted 
a shorter survival were large tumor volume, a history of weight reduction, and a low 
Karnofsky score (Table 3). 
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TABLE 3 
η ß SEj Ρ 
UICC-stage (1987) 
Τ 
Ν 
Μ 
V 
tumor size 
tumor type 
hemoglobine 
weight reduction 
Karnofsky score 
age 
sex 
121 
121 
121 
121 
121 
106 
121 
112 
112 
108 
121 
121 
0 8306 
0 5305 
0 8488 
1 2304 
0 5311 
0 0682 
0 0934 
-0 2032 
-0 8063 
-0 0462 
0 0056 
-0 0393 
0 1948 
0.1750 
0 2506 
0 2666 
0 2505 
0 0305 
03334 
0.1050 
0 2605 
0 0134 
0 0097 
0 2577 
0.0000 
0 0024 
0 0007 
0 0000 
0 1206 
0 0252 
0.7794 
0 0531 
0 0020 
0 0005 
0 5615 
0 8788 
Table 3. Results from the univariate Cox's regression analysis of the influence of the clinical 
variables at the beginning of the treatment on the survival in renal cell carcinoma 
Karyometry features 
The karyometnc measurements were tested for inter-
individual reproducibility among three technicians. For only three of 32 karyometnc 
features discrepancies were found among the technicians: the same observer scored 
significantly higher values for one feature (MH3) and differences were found for two 
other features (MAREA, MIOD). This resulted in a higher percentage of explained 
variance due to the observers compared to the total variance (2%, 6%, 8% 
respectively). For the other features the explained variance was less the 1%. 
Comparison with the percentage explained by the variation between slides showed 
that differences between observers might be of minor importance: percentages 
explained by the variation between slides was 85%, 71%, and 68% respectively for the 
features (MH3, MAREA, MIOD) and 78% to 93% for the remaining features. 
The mean number of morphologically different tumor areas 
as marked by the pathologist per tumor was 2.05 (range 1 to 5) and was not 
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correlated with survival (P>0.10, Cox regression analysis). 
Univariate analysis of the karyometric features showed a 
correlation between several nuclear characteristics and survival (Table 4). 
TABLE 4 
feature η 
subpopulation-depend ent 
L MPASS 
LSDOD 
U MAREA 
U SDIOD 
UMH3 
D2cDI 
D5CER 
D MAREA 
D SDAREA 
DMFPE 
DMBEN 
0 SDBEN 
DSDOD 
DMIOD 
D SDIOD 
DMH3 
subpopulation-independent 
SE. 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
115 
-0.1449 
-8.8587 
0.0340 
0.1133 
5.9251 
0.0609 
0.0407 
0.0161 
0.0443 
10.5628 
0.9138 
4.7412 
9.9105 
0.0583 
0.1117 
4.9692 
0.0665 
4.0352 
0.0169 
0.0397 
1.8854 
0.0280 
0.0201 
0.0081 
0.0160 
5.1429 
0.4493 
1.6933 
3.8077 
0.0251 
0.0453 
2.0552 
0.0294 
0.0281 
0.0436 
0.0043 
0.0017 
0.0290 
0.0427 
0.0457 
0.0057 
0.0400 
0.0420 
0.0051 
0.0092 
0.0200 
0.0136 
0.0156 
SIOD 
MEDH4 
L 
U 
D 
S 
MED 
2c0l 
ScEB 
AREA 
BEN 
FPE 
H3 
H4 
ЮО 
oo 
115 0.1369 
115 -1.1872 
lowvtt ГПМЛ population value 
hlgheit mean population value 
(D - U - L) drft between value· of highest and lowest population 
dirt between 15th and 65th percentile of merged population« 
medtan value of aH populations merged 
• 2c Deviation index 
• 9c Exceeding rate 
• nuclear profile area 
0.0552 0.0131 
0.5995 0.0477 
- banding measure difference m maximal and minimal value In amocthed difference Freeman chain code 
• form PE 
• Marxowan texture feature inverse difference moment 
m Markovian texture feature rotation moment 
* Integrated optical demiiy 
- optical demlty 
> nuctoar shape fasono. numbs« of pests through threshold of smoothed difforme· Freeman chain cod* 
Table 4. Univariate regression 
cell carcinoma. 
analysis according Cox of karyometric features and survival in renal 
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Of the nineteen karyometric features that were related with 
survival, two were subpopulation independent features. Eleven of the subpopulation 
dependent features that correlated with survival were features describing differences 
between tumor areas within the tumor. Karyometric features that showed best 
correlation with survival were variations in nuclear shape as described by the standard 
deviation of the bending energy (SDBEN), variances in nuclear size (SDAREA) and 
'coarseness' of the chromatin as measured by the inverse difference moment of the 
requantitated pixel value cooccurrence matrix (Markovian feature H3) (10). 
Flowcytometric features 
Diploidy was found in 30 samples (47.8%), aneuploidy in 41 
(53.2%). Univariate analysis of the flowcytometric features revealed a correlation 
between the place of the first G„G,-peak and survival (P<0.05, Cox's regression 
analysis). The presence of aneuploidy in the tumor was neither significantly correlated 
with survival nor with tumor stage, the presence of metastases, or venal invasion 
(p>0.05, chi-square test). 
Multivariate analysis 
analysis. 
TABLE 5 
Table 5 shows the results of the Cox multivariate regression 
Î 
0.Θ748 
•0.0398 
•0.7400 
SE8 
0.2253 
0.0144 
0.2803 
Ρ 
0.0001 
0.0058 
0.0083 
Clinical features 
UlCC-stage (1987) 
Karnofsky score 
weight reduction 
Karyometric features 
D SDAREA 0 0436 0.0184 0.0178 
(anisokaryosis) 
Table 5. Multivariate Cox's regression analysis of clinical and karyometric features with survival of 
patients with a renal cell carcinoma. 
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Within this analysis the clinical variables tumor UlCC-stage, the presence of 
weight reduction at time of diagnosis, and the Karnofsky score were the most 
important characteristics for survival. Besides these clinical characteristics the 
karyometric feature variation of the standard deviation of the nuclear size in different 
areas of the tumor showed additional prognostic significance. To study the significance 
of karyometric analysis in high-stage patients multivariate Cox analysis was performed 
on all UlCC-stage 4 patients with known karyometric analysis (n = 52). Similar to the 
findings in the entire group, the karyometric analysis offered prognostic value as did 
the clinical characteristics. However, in the high-stage tumor group the highest value 
for the karyometric texture feature describing chromatin pattern coarseness per tumor 
(H3, inverse difference moment) was the best predictor of survival of both the 
karyometric and clinical features. The presence of weight reduction at diagnosis 
offered only additional prognostic value to this karyometric feature. This indicates that 
karyometric analysis was the most important prognostic factor is this group. 
With the best predictors for survival, both the clinical (tumor stage, weight 
reduction, and Karnofsky score) and karyometric features (variation in nuclear size) 
we were able to form prognostic groups in the entire population of 121 patients. The 
results are shown in Table 6 and Figure 3. 
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TABLE 6 
XBeta = ( 0.Θ75 * stage) + 
(-0.040 * Kamorsky score) + 
(-0 740 * weight reduction) + 
( 0.044 * D SDAHEA) 
stage : UlCC-stage (1987) 
Kamosfky score : performance status (0-100) 
weight reduction : weight reduction prior to diagnosis (=-1), else 2. 
D SDAREA : difference of SD of nuclear size within the tumor. 
RCC-score XBeta 3-yrs 
survival (%) 
good prognosis 
intermediate prognosis 
poor prognosis 
i-2.3 
-2.3 - -1.0 
> -1.0 
39 
54 
28 
80 (65-95) 
41 (27-55) 
32 (6-37) 
Table 6. Calculation of the RCC-score based on the features found in the Cox's multivariate 
regression analysis and number of the patients in the prognostic groups based on the RCC-
score. 
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Figure 3. Kaplan-Meier survival curves for the three prognostic groups. 
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The prognostic score (RCC-score) was calculated using the formula found in 
the Cox regression analysis. Subdivision of the patients group into three groups based 
on the XBeta value resulted in significantly different Kaplan-Meier curves (Figure 3). 
Good prognosis (3-years survival: 80%) was found for patients (n=39) with a XBeta 
value lower than -2.3, whereas patients (n=28) with a XBeta value higher than -1.0 
had a poor prognosis (3-years survival 21%). The 3-years survival for the patients with 
intermediate prognosis was 41% (n=54). 
DISCUSSION 
The main problem in the management of patients with RCC is the 
unpredictable clinical course of the tumor. Since tumor grading of RCC is hampered 
by considerable tumor heterogeneity we investigated a karyometric grading system for 
the quantification of differences within the tumor presumably associated with 
heterogeneity. The karyometric grading was tested for its additional prognostic value 
to classical and flowcytometric characteristics. 
Karyometric analysis, i.e. the quantification of cell nuclear features in light 
microscopy has been successfully applied for the grading of several cancers. In renal 
cell carcinoma, Tosi and associates and Bibbo and associates found a positive 
correlation between morphometric results and survival in patients with stage-I disease 
(11,12). Murphy and associates described a nuclear shape analysis which allowed the 
correct assignment of outcome of localized carcinoma which may become available in 
clinical practice (13). From the studies done so far it has become clear that nuclear 
size as well as nuclear shape are of prognostic value in RCC. However, the number of 
patients in these studies was rather small. Moreover, tumor areas for analysis were 
often chosen at random and none of the studies distinguished different parts within 
the tumor. 
Flow cytometry is known as an easy and reproducible method to determine 
deoxyribonucleic acid (DNA) content. Otto and associates found a positive relation 
between the DNA content and risk for recurrence and advised to use this technique 
in selecting patients for adjuvant chemotherapy after nephrectomy (14). A higher 
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prognostic significance could be obtained by combining flow cytometry and nuclear 
grading. Ljungberg and associates suggested that DNA content in RCC might be a 
superior prognostic indicator than clinical or histological features (15). These results 
were confirmed by Rainwater and associates in a study with a long follow-up (16). On 
the other hand Currin and associates recently could not find a significance of flow 
cytometry as a TNM stage-independent impact on prognosis and re-opened the 
discussion on the widespread clinical application of ploidy status (17). The ploidy 
patterns in the different tumor stages in our study were largely in agreement with the 
findings of Currin and associates We confirmed absence of significant correlation 
between ploidy and survival. Like Currin and associates, in our study only one sample 
of the tumor was analyzed. Other studies using multiple samples from the same tumor 
found a considerable heterogeneity in RCC (14,15,18). Whereas the distribution of 
diploidy and aneuploidy found in low stage (T, and T2) tumors in our study is similar 
to earlier findings, the number of aneuploid high-stage tumors is relatively low (59%) 
and may illustrate the inaccuracy of only one sample as taken in these larger tumors. 
Tumor heterogeneity in the larger tumors is most likely the explanation for the lack of 
correlation of ploidy with survival. 
From these flowcytometric studies we learned that considerable heterogeneity 
of tumor cell populations exists in RCC. The origin of multiple cell populations within 
the same tumor can most likely be found in genetic instability, a trait of aggressive 
neoplasms. Karyometric analysis offers a means to quantify nuclear features within the 
cell clones. Hence, the technique can be used to obtain a measure for the level of 
phenotypical differences between the cell clones within the same tumor. We 
postulated that the degree of nuclear phenotypic differences within the tumor as 
assessed by karyometric analysis is indicative for tumor heterogeneity and thus may in 
fact correlate with genetic instability in the tumor development. Since increased 
genetic instability might result in more rapid progression to malignant, e.g. 
metastasizing phenotype the karyometric grading of tumor heterogeneity might be a 
good predictor of tumor malignancy. 
In the present study morphologically different areas within the tumor were 
selected by the pathologist and karyometrically analyzed. Whereas the number of 
marked tumor areas per tumor was of no prognostic value, data from our study 
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indicate prognostic value for the degree of heterogeneity as assessed by the 
differences of karyometric phenotype between subpopulations. Heterogeneity in DNA 
content (2cDI), nuclear size, shape, and chromatin pattern were all correlated with 
survival, which is in agreement with other studies (11,12,13). 
In tumors already metastasized at time of diagnosis (stage IV) karyometric 
analysis appeared to be the best predictor of survival. However, the karyometric 
features describing heterogeneity in the tumor were less predictive of survival in this 
patient group. It is therefore tempting to speculate that in metastasized disease 
malignant behaviour of the tumor is more determined by the presence of malignant 
cell clones rather than by the chance of development of an even more malignant 
phenotype. In this light, we consider high-stage tumor as completely dedifferentiated 
cancer that gained full malignant potential. 
To evaluate the additional value of karyometric tumor grading and 
flowcytometry to classical tumor characteristics we also analyzed several clinical 
characteristics. 
The stage of the tumor, including invasion of the vena cava, and the presence 
of lymph nodes or metastases allow to make subdivisions of patients with regard to 
survival. The local extent of tumor at the time of surgery is the most important single 
variable in determining survival (19). Because the TNM(V) classification explicitly 
defines the anatomic extent, it is often at the basis of further stratification of risk 
factors (19,20,21). The patients in the current study were classified according to the 
TNMV and Robson system and it appeared that a higher stage was related to a lower 
survival. More explicitly, not only tumor stage but also the presence of lymph node or 
distant metastases showed to be an important prognostic indicator for survival. In the 
univariate analysis they all appeared to be of prognostic significance. It is now clear 
that vena cava invasion, when curatively operated, is not a prognostic indicator as 
such (22). The reason is that it is often associated with factors that heavily influence 
survival, as was also seen in our study (20). 
Other features, related to survival, were performance status (Karnofsky score) 
and a history of weight reduction. These obvious clinical characteristics were also 
found by others, and should be included in a prognostic factor analysis (19,21). Size of 
the primary lesion, indirectly related to the T-stage, was not an independent 
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prognostic factor, as was also seen by others (21). RCC are divided in the literature 
into clear cell, granular cell, spindle cell, and oncocytoma type tumors. Although 
oncocytomas are characterized by a favourable clinical course, the prognostic 
importance of the other tumor types is not clear (22-26). In our series oncocytomas 
were excluded and no correlation with survival was found for the other tumor types. 
To obtain features that independently predict survival, a multivariate analysis 
was performed. It was obvious that tumor stage, history of weight reduction, and the 
karyometnc features that illustrate the heterogeneity of the tumor appeared to be the 
most important prognostic factors in patients with RCC. With these factors we were 
able to define certain risk groups that can be used for treatment decision and the 
development of future clinical trials. 
We conclude that clinical and karyometnc features correlate with tumor 
behaviour. Moreover, a combination of karyometry and clinical data offers the best 
prediction of survival. Tumor heterogeneity, as quantificated by karyometric analysis 
plays an important role in tumor behaviour. The factors analyzed in this study may be 
of use to individualize the treatment of patients with RCC. 
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SUMMARY 
The risk of local recurrence or development of distant metastases in patients 
with a locally confined (T,^N0M0) renal cell carcinoma (RCC) is 45-65%, and 
additional treatment is warranted to improve survival rates. Adjuvant immunotherapy 
might be beneficial to kill micro-metastases that exist at the time of surgery. Because 
this kind of treatment has considerable side-effects, selection of patients based on 
prognostic factors is mandatory. 
Material from 52 patients with T,.jN0MB tumors was studied among a 
population of 121 patients with all stages of RCC. During follow up of at least 3 
years, 21 patients developed local recurrence or distant metastases. 
In an univariate analysis for risk of progression, of the clinical (age, sex, 
weightloss, performance status, and serum hemoglobin concentration) and 
pathological characteristics (T stage, tumor size, and tumor type), only performance 
status appeared to have prognostic significance; the karyometric characteristics of 
nuclear shape, nuclear size, and chromatin patterns were also predictors of tumor 
progression. In a multivariate analysis differences in chromatin pattern were the best 
predictors of survival; only Τ stage added to the prognostic significance. 
We conclude that karyometric analysis is a powerful tool in predicting tumor 
progression in patients with clinically localized RCC. Tumor heterogeneity expressed 
as different nuclear chromatin patterns was the most powerful indicator of 
progression. Those findings are particularly valuable in stratifying RCC patients for 
follow up shedules or even adjuvant treatments. 
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INTRODUCTION 
Renal-cell carcinoma (RCC) accounts for 2-3% of human malignancies. The 
overall 5-year survival rate is 30-60% '. In 50% of patients, the carcinoma is confined 
to the kidney. For these patients radical surgery offers the only chance of cure. The 5-
year survival rate of these patients ranges from 50 to 90 % г"5. Therefore, unless the 
tumor seems to be susceptible to radical surgery, the outcome remains unpredictable 
and a substantial number of patients will die from RCC. The deaths will probably be 
due to outgrowth of micro-metastases that cannot be detected by radiologic 
examinations, but already exist at the time of tumor nephrectomy. 
The rationale of adjuvant chemotherapy or immunotherapy after tumor 
nephrectomy in low-stage RCC is based on the use of animal models. In animal 
models, immunotherapy has been effective, especially in microscopic disease more 
than in macroscopic disease "7. However, in humans the situation is not so clear. In 
patients with colon carcinoma with only regional nodal involvement, adjuvant 
chemotherapy has improved survival rates 7. In patients with localized RCC, adjuvant 
immunotherapy or chemotherapy might improve the outcome of the disease after 
tumor nephrectomy. Immunotherapy can have serious side effects, so it must be 
carefully considered and administered only to specially selected patients. Knowledge 
of factors that can be used to predict tumor recurrence or progression into metastatic 
disease is essential in the selection of appropriate patients. 
Clinical and histopathologic characteristics have been studied, and prognosis 
has been shown to correlate well with performance status, tumor stage, and tumor 
grade > 5. In view of the low reproducibility of tumor grading, quantitative light 
microscopic techniques with image analysis have been used to describe histological 
tumor features °. Several karyometric features have been found to correlate with 
prognosis ·"". 
We have investigated the use of clinical, pathologic and karyometric features 
of patients with clinically localized RCC for the prediction of local recurrence or the 
development of metastatic disease. 
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MATERIAL AND METHODS 
Patients 
Of a total of 121 patients, we analyzed data on 52 patients (31 men; 21 
women) with clinically localized RCC treated between 1983 and 1989 with radical 
nephrectomy. Their median age was 57.4 years (range, 29-93 years). The followup 
period was at least 3 years (median, 60 months). 
Radiographic staging was done with computed tomography of the abdomen 
and tomography of the lungs. No evidence of lymph node metastases was found in 
pathologic examination of lymphadenectomy specimens. The patients could be 
classified according to the tumor-nodes-metastases (TNM) system developed by the 
International Union against Cancer, which classifies cancer cases according to the 
anatomic extent of disease '2. Localized disease was defined as stage T,.3N0M0. This 
means that all patients potentially could be operated on curatively. 
Clinical features 
Various clinical features that had earlier been found to be associated with the 
outcome of the disease were recorded. Besides age and sex, they included 
performance status (Karnofsky score) and a history of weightloss. Serum hemoglobin 
concentration was also tested. Of the pathologic characteristics, Τ stage, tumor size, 
and histologic tumor type were recorded. 
Karyometric features 
All paraffin-embedded material was reviewed by one pathologist (H.E.S.). 
Morphologically different tumor areas were marked for karyometric analysis. The 
selection of areas was based on differences in histology (papillary and non-papillary) 
or cytology (clear, granular, and spindle cell). Karyometric analysis consisted of 
nuclear morphometry, densitometry, and chromatin pattern analysis with a PC-based 
image-analysis system (VFG-framegrabber board, Imaging Technology, Woburn, MA) 
in a Compaq 386s personal computer). Image handling and analyisis software was 
written in TIM (TEA, Dordrecht). For analysis, 4^m-thick paraffin-embedded 
sections were deparaffinized and Feulgen-Schiff stained at room temperature. In 
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figure 1 an example is given of a light-microscopic image that is processedin steps to 
the image used for karyometric analysis. After shading correction and image filtering a 
local segmentation procedure was performed based on the grey-value histogram in the 
subimage. 
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Figure 1. Summarize of the image processing steps: 
A. original black and white image 
B. tresholded and segmented image 
С verification ¡mage for selection of nuclei of interest after karyometric 
analysis 
Because the pathologist marked in each tumor morphologically different 
tumor areas, heterogeneity could be calculated as follows. In all tumors for every 
nuclear feature the tumor area with the highest and lowest value and their differences 
was determined. We also analyzed the benefit of karyometric analysis of different 
tumor areas marked by the pathologist compared to at random measurements in the 
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tumor. Hence, besides data of different tumor areas all values of the tumor areas 
were merged and median and difference of 15* and 85m percentiles were calculated to 
obtain a subpopulation independent measure of tumor heterogeneity. 
The karyometric measurements were tested for inter-individual reproducibility 
among three technicians. The technicians performed independently karyometric 
measurements of nuclei in the marked areas. The measured feature values were 
analyzed for their inter-observer agreement using two-way ANOVA 13. 
Statistical methods 
The time from tumor nephrectomy to tumor progression was studied. 
Progressive disease was defined as renal fossa recurrence or development of distant 
metastases. The Kaplan-Meier method was used to estimate the progression rate. 
Differences obtained were tested for statistical significance with the log-rank test and 
the Wilcoxon test. The 3-year tumor progression rates, with 95% confidence intervals, 
were calculated with the Kaplan-Meier method. 
Cox's univariate and multivariate regression analyses (i.e., proportional hazard 
model) were performed to estimate the influence of the clinical and karyometric 
features on time to tumor progression. Both forward and backward stepwise selection 
procedures were used to find the best model for predicting the disease-free interval. 
The selection procedure was performed in two parts. In part I, the selection was used 
to find all clinical variables to define either the best or an equivalent model. The 
Bonferroni correction was used for model entry of a variable. The same procedure 
was also performed on the karyometric feature groups. In part II we used the 
selection procedure on both clinical and karyometric features selected in the previous 
step. 
RESULTS 
Clinical features 
During the followup period 21 (40%) patients developed progressive disease; 
15 (71%) of the 21 died of RCC. The 3-year progression rate was 33% for T, (n=5), 
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29% for Т
г
 (η=23), and 47% for T3 (η=24). The differences between the progression 
rates were not significant in the Wilcoxon test (P = 0.19) or the log-rank test (P = 
0.17). 
In the univariate Cox's regression analysis of the clinical features, only the 
patients with low Karnofsky scores at the time of diagnosis were at risk to develop 
tumor progression, and the relation was significant (P < 0.05). Tumor stage, patient 
age and sex, serum hemoglobin concentration at the time of diagnosis, histologic 
tumor type, tumor size, and history of weight loss, were not significantly related to 
progression (P>0.10). The results of the univariate analysis are shown in Table 1. 
TABLE 1 
Beta SBeta 
Sex 
Age 
Karnofsky score 
Weight loss 
Hemoglobin 
Τ stage 
Tumor size 
Tumor type 
Table 1. Univariate Cox's 
0.674 
-0.0079 
-0.0508 
-0.7720 
-0.100 
0.686 
0.094 
0.350 
regression analysis 
0.450 
0.016 
0.243 
0.487 
0.178 
0.408 
0.071 
0.520 
0.1343 
0.6241 
0.0369 
0.1130 
0.5722 
0.0927 
0.1836 
0.5006 
of clinical features and tumor 
0.041 
0.000 
-0.137 
-0.064 
0.000 
0.076 
0.000 
0.000 
progression. 
Karyometry features 
The karyometric measurements were tested for inter-individual reproducibility 
among three technicians. For only three of 32 karyometric features discrepancies were 
found among the technicians: the same observer scored significantly higher values for 
one feature (MH3) and differences were found for two other features (MAREA, 
MÍOS). This resulted in a higher percentage of explained variance due to the 
observers compared to the total variance (2%, 6%, 8% respectively). For the other 
features the explained variance was less than 1%. Comparison with the percentage 
explained by the variation between slides showed that differences between observers 
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might be of minor importance: percentages explained by the variation between slides 
was 85%, 71%, and 68% respectively for the features (MH3, MAREA, MIOD) and 
78% to 93% for the remaining features. 
The number of morphologically different areas per tumor was not correlated 
with tumor progression (P>0.10). Of the nine karyometric features that were related 
to progressive disease, only one was an area-independent feature. Differences in 
karyometric-feature values between selected tumor areas were highly correlated with 
progression. Univariate analysis of the karyometric features showed a correlation 
between several nuclear characteristics and progression (Table 2). 
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TABLE 2 
Beta SBeta 
L2CDI 
UMBEN 
D SDAREA 
D MSCAT 
DMH1 
DSDH1 
DMH3 
DMH5 
MEDPASS 
-0 234 
2 243 
0 102 
1281 
5 934 
6 322 
60 002 
2 799 
0 254 
0 1 1 7 
1 108 
0 041 
0 454 
2 009 
2 424 
19 386 
1 001 
0 121 
0 0464 
0 0429 
0 014 
0 0048 
0 0032 
0 0091 
0 0020 
0 0051 
0 0351 
0118 
0 122 
0 1 7 0 
0 206 
0 2 1 9 
0 185 
0 232 
0 204 
-0 132 
Note L= lowest population value 
U= highest population value 
D= U-L 
MED= median value for entire tumor (all populations merged) 
2cDI= 2c Deviation Index (Boeking, 1984) 
MBEN= mean bending nuclear shape factor (based on smoothed differences in Freeman 
chain code), describing nuclear irregularity 
SDAREA- standard deviation of nuclear area 
MSCAT = mean scatter vanance in pixel values (texture feature) 
MH1= mean H1 (Markovian feature entropy) 
SDH1= standarddeviation HI 
MH3= mean H3 (Markovian feature inverse difference moment) 
MH5= mean H5 (Markovian feature inverse rotation moment) 
MEDPASS = median value in tumor of PASS (nuclear shape factor based on smoothed 
differences in Freeman chain code) 
Table 2 Karyometnc features significantly correlated with tumor progression in univariate Cox 
regression analysis 
Multivariate analysis 
Table 3 shows the results of the multivariate Cox regression analysis. Several 
karyometnc features could be entered in the model. 
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TABLE 3 
Step Beta SBeta Ρ 
1.DMH3- 61.330 19.90 0.002 
2. Tumor stage 1.086 0.492 0.027 
' Differences between populations with highest and lowest values of the inverse difference moment 
of the co-occurence matrix (Markovian texture feature) within tumor. 
Table 3. Multivariate Cox regression analysis of clinical and karyometric features and tumor 
progression. 
A most significant result was found for the differences in chromatin pattern 
between tumor subpopulations, as described by the inverse difference moment of the 
co-occurence matrix (Markovian texture feature MH3). Otherwise, only Τ stage 
showed additional prognostic significance. In the multivariate analysis, sex, age, 
presence of weightloss at the time of diagnosis, histologic tumor type, tumor size, and 
Karnofsky score did not add to prognostic significance. 
DISCUSSION 
The chance of local recurrence or development of distant metastases in 
patients with locally confined RCC (T,.3 N0 M0) is 45-65% , 1 U . Moreover, the 
prognosis of patients with progressive disease after radical tumor nephrectomy for a 
locally confined tumor is very poor: a mortality rate of 74% at 1 year has been 
recorded ". 
Many clinical trials have studied the role of immunotherapy in patients with 
RCC ". In patients with metastatic disease, 14-30 % reacted positively to this type of 
therapy 1"·1 7. Especially patients with good performance status, relatively low tumor 
burden, no central nervous system or bone metastases, and a long interval between 
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nephrectomy and appearance of metastases seemed to benefit from immunotherapy 
" · " . Because patients with a low tumor burden react better to immunotherapy, 
patients with localized disease might benefit from this kind of treatment. In these 
patients early detection of progression is neccessary. However, no applicable 
technique has been developed for the detection of micrometastases or remaining 
tumor cells in the renal fossa that can be used to predict the chance of tumor growth 
after radical nephrectomy for locally confined RCC. To identify patients at risk a 
prognostic factor analysis is mandatory. In the present study, we investigated the use 
of clinical, pathologic, and karyometric features to predict tumor progression of locally 
confined RCC. 
Because, for decades, the surgical approach to RCC has been the mainstay in 
treatment, the histologic results and material have been applied to determine 
prognosis я . Factors described in the literature are tumor-cell type, nuclear grade, 
mitotic rate, tumor heterogeneity, and cytologic features 21'27. More recently, 
karyometric analysis has been shown to be of prognostic significance. Several authors 
found a positive correlation between morphometric results and survival in patients 
with stage I disease "Л Others found a prognostic discriminant in the nuclear size of 
all RCCs M. Murphy and associates described a nuclear-shape analysis that predicts 
outcome of a localized carcinoma and might become available for clinical use " . 
Therefore nuclear size and shape are of prognostic value in RCC. 
Flow cytometric studies have shown considerable heterogeneity of tumor-cell 
subpopulations in RCC Μ Μ . We tried to develop a routinely applicable method of 
quantitative tumor grading, taking tumor heterogeneity into account. Morphologically 
different tumor areas were marked and karyometrically analyzed. The number of 
marked tumor areas per tumor was of no prognostic value, but the karyometric data 
in the different areas had predictive value for tumor recurrence. Like Murphy et al. ", 
we found a shorter time to tumor progression or local recurrence in patients who had 
tumor-cell populations with irregularly shaped nuclei. Unlike Tosi et al. 9, we found 
absolute nuclear size to have no predictive value. However, the presence of 
heterogeneity in nuclear size (anisokaryosis) in the different tumor areas was 
significantly related to tumor progression. The importance of heterogeneity is also 
illustrated by the results of the chromatin-texture analyses: recurrence or progression 
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is earlier in patients with a high variance in nuclear chromatin patterns as measured 
by the Markovian texture features. 
Although tumor heterogeneity has been described for several tumors and its 
correlation with prognosis has been reported, we can only speculate on the reason for 
the worse prognosis of heterogeneous tumors. Most likely, the genetic instability of 
the tumor, reflected by heterogeneity, is the reason. Hence, karyometric analysis, 
which quantifies the nuclear phenotypic characteristics, not only describes the extent 
of nuclear atypia in the tumor but also provides information on tumor biology. The 
presence of large differences in phenotype between populations, as described by 
karyometry, could be a useful measure of genetic instability. Presumably, the chance 
of development of a high-grade malignant phenotype increases in heterogeneous 
tumors; this would account for the prognostic value of karyometric analysis. 
To obtain features that predict recurrent disease independently, we 
performed a multivariate analysis. Of the clinical and karyometric characteristics, the 
features describing variance in chromatin pattern within a tumor were significantly 
correlated with the chance of local recurrence or of development of metastatic disease 
in the multivariate model. Of all the other clinical features, only tumor stage yielded 
additional information. 
We therefore emphasize that the features of karyometric analysis can be used 
to predict the outcome of patients with localized RCC. In patients with high 
anisokaryosis, irregularly shaped nuclei, but above all variance in chromatin pattern, 
there is a considerable chance of progression. These patients must be followed more 
closely or even treated with adjuvant immunotherapy from the onset after radical 
nephrectomy. In a recently activated randomized phase-Ill study that uses adjuvant 
subcutaneous recombinant interleukin-2 versus no treatment in patients with RCC and 
no evidence of disease after tumor nephrectomy and lymphadenectomy, we will 
include the karyometric characteristics to evaluate their prognostic significance in a 
prospective study and to individualize patients followup schedules. 
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CHAPTER IX 
SUMMARY AND PROSPECTS 
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1. Summary 
In Chapter 1.1. the rationale of research on prognostic factors in urologica] 
oncology has been discussed and it is concluded that prognostic factors can be clearl) 
defined and that a 'prognostic stratification' forms the basis of the design of treatmenl 
protocols. In this context it is concluded that the contribution of the statistician is 
essential, and it is imperative that the statistical analysis have to be performed in an 
unbiased manner. In Chapter 1.2. an overview is given of the prognostic factors in germ-
cell tumors. Several histological classifications and staging models are described and theii 
importance for treatment decision and prognosis is highlighted. Using these 
characteristics in combination with biochemical parameters, we are able to define certain 
risk groups. These results are at the basis for further research on prognostic factors ir 
these tumors. In Chapter 1.3. a summary is given of the state of the art on prognostic 
factors in metastatic prostate cancer. Particularly the biochemical markers are of interesl 
for the prognosis and in monitoring progression. These factors are, in addition to the 
histological and radiographic parameters, also meaningful for the prognosis and for the 
individualization of treatment. In Chapter 1.4. the prognostic factors of patients with 
superficial bladder cancer are discussed. A combination of clinical and pathologic 
characteristics is useful to predict the likelihood of recurrence. Because new treatmenl 
options have been developed, the value of these parameters is becoming increasinglj 
important. In Chapter 1.5. a summary of the prognostic factors in renal-cell carcinoma 
is given. With the clinical, pathological, and biochemical parameters already known, the 
course of this cancer may not be predicted. Most of the sofar known parameters are 
summarized here. Recent progress on cytogenic and karyometric characteristics of tumoi 
cells as to prognosis predictors is also discussed. 
The results of the review of prognostic factors as given in chapter I, formed the 
impetus for the investigations carried out for this thesis. Based on the knowledge of these 
prognostic factors, new investigations were initiated with the aim to define better the 
prognosis for a patient with an urologjcal tumor and judiciously to select the appropriate 
treatment and follow up schedules. 
In Chapter II an investigation is done of the value of the classification models ol 
the European Organization for Research and Treatment of Cancer (EORTC) and of the 
144 
Indiana (US) group for patients with disseminated germ-cell tumors. Both models were 
useful for predicting the survival of patients treated with induction chemotherapy. As an 
additional prognostic parameter, the size of the retroperitoneal tumor before and after 
:hemotherapy appeared to be of importance. Radiographic changes in the size of the 
retroperitoneal tumor during chemotherapy appeared to be of considerable prognostic 
significance with regard to the histology of the tissue resected after chemotherapy and 
therefore for prognosis. With this knowledge, further individualization of the treatment 
for these patients may be designed. 
In Chapter Ш an update is given of prognostic factors in disseminated prostate 
cancer. This side-study of a well-documented trial of hormonal treatment showed that 
using performance status, haemoglobin and alkaline phophatase as group criteria, one 
may define the corresponding risk groups. Especially for the high-risk group, new 
treatment modalities may be useful to improve the prognosis. 
In Chapter IV an investigation is done of the exact value of the biochemical 
markers, alkaline phosphatase, prostate acid phosphatase and prostate-specific antigen 
in monitoring the hormonally treated prostate cancer patient. Especially the PSA was 
useful for this purpose and may permit the omission of routine bone scanning. This 
procedure is now being adopted in new trials. 
In Chapter V a controversial subgroup of patients with superfical bladder cancer 
has been examined. The results of the treatment of patients with pT,G3 bladder tumors, 
gathered by a cooperative group of urologists in the south-eastern part of The 
Netherlands, were evaluated retrospectively. None of the prognostic factors examined, 
appeared to be of additional prognostic value in these selected patients. It was concluded 
from this study that additional treatment with intravesical immuno-, or chemotherapy, or 
radiotherapy, after the initial transurethral resection is mandatory, to improve survival. 
In Chapter VI a side-study on prognostic factors is performed in patients with 
superficial bladder tumors treated with intravesical instillations. In this well documented 
trial, multiplicity and the location of the tumor were of prognostic significance for the 
recurrence-free interval. Especially location of at least one tumor in the regions trigone 
and posterior wall of the bladder were an additional risk factor for recurrence after the 
first initial intravesical treatment. It was concluded that especially these patients should 
be followed more closely. 
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In Chapter VII a prognostic factor analysis of clinical, flowcytometric and 
karyometric characteristics in renal-cell carcinoma is performed. In this heterogeneous 
group of all stages of renal-cell carcinomas it was obvious that from among the clinical 
factors only performance status and a history of weight loss were of prognostic 
importance. Those karyometric parameters which characterize the heterogeneity of the 
tumor, were also of importance for the prognosis for patients with renal-cell carcinoma. 
Ibis heterogeneity may imply biological instability of the tumor and thus related to a 
shorter survival of the patient. The flowcytometric characteristics were not of additional 
prognostic significance, but this may be caused by the fact that only one sample of the 
tumor was studied. The aforementioned heterogeneity was thus not available for analysis. 
In Chapter Ш a subgroup of T^NjM, renal-cell carcinoma was subject of 
investigation. In particular it confirmed the value of the karyometric characteristics; the 
karyometric characteristics which stand for heterogeneity were of utmost importance. In 
this context karyometry informs us on the malignant potential of the tumor and may help 
us to select patients for additional treatment, for instance immunotherapy. 
2. Prospects 
"Is this the future or is the future already present?" 
Prognostic factor analysis in urologjcal cancer will continue to play an important 
role in the future. With the number of treatment options on the increase, their evaluation 
will need exact prognostic factors. Only in this way we will be able to improve our 
treatment results for carcinoma patients. A phase III randomized trial on treatment 
should also be accompanied by a so-called side-study of prognostic factors. These well-
documented trials gives one the opportunity to identify the exact values of prognostic 
Factors in relatively homogeneous groups of patients. In order to be able to draw 
meaningful conclusions it is often necessary to recruit a large number of patients in a 
relatively short period of time. Therefore, special effort must be made to develop large 
international multicentre trials. This gives additional merit to international organisations 
like the European Organization for Research and Treatment of Cancer (EORTC). The 
value of a prognostic factor analysis is also increased by these large number of patients, 
treated within a short period of time, and answering the same inclusion and exclusion 
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:riteria. Only in this way, an accurate evaluation of the treatment for the individual 
patient is guaranteed. 
In order to make progress in urological oncology, it is necessary to continue the 
research on prognostic factors. The value of prognostic factors must be defined for the 
various levels of cancer and the patient whom it affects. In the field of the basic research, 
cytometric, cytogenic and molecular abnormalities must be more extensively investigated 
and may, in the future be included in a routine clinical setting. 
Germ-cell tumors 
For disseminated germ-cell tumors, timing and extent of treatment is still 
investigational. New prognostic factor analysis of large series of patients will better define 
risk groups (Mead et al). Especially patients who have a high probability of failing 
treatment will be included in new experimental studies. Because these very intensive 
chemotherapy schedules still have severe and potentially lethal side effects, the research 
on prognostic factors, indicating these poor risk patients is vital. 
For this rare tumor, it is mandatory to develop large multi-centre studies in order 
to improve the relatively good prognosis. Especially further individualization of treatment; 
e.g. the number of cycles of chemotherapy or the exact indication for lymph node 
surgery, must be the goal. Also a better monitoring of the patients during chemotherapy 
will give an indication for the individualization of treatment schedules. 
Germ-cell tumors have been classified mainly as seminomas and nonseminomas, 
with consequences for their treatment. In the near future, also other histological 
parameters (e.g. vascular and lymph vessel invasion) will be included in treatment 
strategies because of their prognostic importance (Sesterhenn et al). In a recently started 
investigation, these histological parameters will be included in the evaluation of treatment 
strategy in the patients. More experimental studies on cytogenics may aid decisions about 
those treatment schedules in the future. 
Prostate cancer 
Every patient with prostate cancer has to be treated on an individual basis. In the 
last fifty years, all patients with metastatic prostate cancer have been treated palliatively 
with hormones with no clear prolongation of survival. Lately, more and more attempts 
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have been made to develop new treatment options. In patients with low stage metastatic 
disease the question if early hormonal treatment gives a better survival and a longer time 
to progression than delayed therapy, is still under investigation. On the other hand, 
patients with extensive metastatic disease may profit from early combination of hormonal 
plus chemotherapeutic treatment. In a pilot trial of chemohormonal therapy for 
metastatic prostate carcinoma, this treatment showed good results and the study is now 
continuing in a large phase III study (Dawson et al.). The inclusion of patients in these 
studies are based on the results of prognostic factor analysis and are good examples for 
future strategy. 
Careful monitoring of the response to treatment of patients with prostatic 
carcinoma has shown great value. In a recently started large study of patients with 
metastatic disease a search will be done for those patients whose reaction to hormonal 
treatment was less than expected from the use of prognostic factors. These patients may 
then be accesable for alternative options in order to improve their survival. 
More basic research will yield additional prognostic factors in the near future, 
relevant with respect to the heterogeneity of the tumor and consequently the variability 
of success of hormone treatment. Sofar attempts to establish a functional relationship 
between the nuclear androgen receptor concentration and the duration of response to 
hormone therapy have been inconclusive. It is not inconceivable that more results will 
come from the detection of new monoclonal and polyclonal anti-androgen receptor 
antibodies. It is probable that the effect of hormonal treatment will be followed by 
measuring the androgen receptor content by occasionally performing biopsies at time 
intervals (Chodak et al). 
One important aspect that we have learned from tumor cell biological evaluation 
is the fact that more aggressive tumors tend to be genetically unstable. This detection of 
heterogeneity in certain tumors has recently been seen in the multifocality with both 
diploid and nondiploid cancer cells present in the same prostate (Greene et al). Also the 
evaluation of tissue PSA heterogeneity in lymphnode metastasis can provide additional 
prognostic value (Hamdy et al). Molecular instabilities in prostate cancer are found in 
mutations in the P53 tumor suppressor gene and can stand for the likelihood of 
progression in these tumors (Effert et al). Also a decreased expression of the intercellular 
adhesion molecule E-cadherin showed biological significance in prostate cancer and may 
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give an indication as to the metastatic potential of the tumor (Umbas et al). 
Bladder tumors 
For superficial bladder tumors a more strict criteria for treatment continues to be of 
interest in the future. From the prognostic factor analysis from previous trials on 
treatment with adjuvant intravesical immunotherapy or chemotherapy we learned that 
not all the patients react identically to treatment. Much progress will be made in the 
research on 'case selection': which patient will benefit the most from which schedule of 
adjuvant intravesical therapy. Therefore, in the new trials on treatment which have been 
initiated recently, a more strict selection of patients has been adhered to. Also 
individualisation of follow-up schedules will be important. 
In the near future the results showing proliferation antigens, growth factors, 
proteolytic enzymes and genetic alterations will exert their clinical impact (Lipponen et 
al). A good example here is the p53 antigen which has been implicated in the 
pathogenicity of bladder cancer (Sidransky et al). More studies are underway further to 
characterize these results and determine if other factors including ploidy, localized loss 
of heterozygosity and mutation at other tumor suppressor loci can be used in join to 
design a system of molecular prognostic markers for bladder cancer. 
Renal cell carcinoma 
For renal-cell carcinoma efforts will be made to clarify the still unpredictable 
clinical course of these patients. It is expected that in the near future we will be able to 
prognosticate more accurate by using cytometric, cytogenic and karyometric parameters. 
A good example is the proliferating cell nuclear antigen (PCNA) which can be used to 
identify patients with early disease which may have a poor prognosis (Cronin et al). The 
reproducibility of these new prognostic factors should still be confirmed. Every newly 
developed marker should be investigated in separate groups of patients in order to 
establish its importance for routine clinical practice. A good example is the nuclear 
morphometry which will be used for routine clinical practice with consequences for the 
management of patients with renal-cell carcinoma. The use is also advocated by several 
other investigations (Gutierrez et al). Next to the already existing staging systems, 
parameters like these will tell us more about the biological behaviour and the 
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aggressiveness of the tumor. The heterogeneous aspect of the tumor will have 
consequences for the follow up schedules and the suitability of adjuvant treatment. 
Until now, the treatment of metastatic renal-cell carcinoma by immunotherapy has 
been characterized by the lack of response and severe side-effects. Progress will be made 
by a decrease of the side-effects of, especially, the immunotherapeutic agents. With the 
use of a prognostic factors analysis, it is becoming more and more clear that selected 
patients react better to this kind of treatment than a random group (de Mulder). With 
these two issues in mind, new trials will therefore be developed to produce a better 
response to these kinds of treatment. 
In a recently initiated study, we include the value of the karyometric analysis in 
a karyometric malignancy index. With the results of this method, the prognosis of the 
individual patient may be predicted with great accuracy. In the near future, further 
individualization of the management of patients with renal-cell carcinoma will be possible. 
This may lead to an improvement in survival of those patients. 
The search for prognostic factors in urological tumors will be continuous. The 
results from this thesis must therefore be at the basis for further research. Every analysis 
on prognostic factors will initiate new investigations in this field. Essential towards this 
goal is a good interaction between basic research and clinical investigations. Success in 
basic research must not lead to complacency in clinical studies and vice versa. Only in 
this collaborative way the best possible prognostic parameters will be found. In the end, 
this is the only way which will lead to the improvement in the indication and the choice 
of treatment and therefore the improvement of the survival of patients with urological 
oncological disease. 
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HOOFDSTUK Χ 
SAMENVATTING EN TOEKOMSTPERSPECTIEVEN 
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1. Samenvatting 
In Hoofdstuk 1.1 wordt de gedachtengang van het onderzoek naar prognostische 
factoren in de oncologische urologie besproken. Geconcludeerd wordt dat het mogelijk 
is de exacte waarde van de diverse prognostische factoren te bepalen en dat deze 
'prognostische stratificatie' als basis kan dienen voor het ontwerpen van nieuwe 
behandehngsprotocollen. In deze context is de bijdrage van de statisticus van essentieel 
belang, mede vanwege het feit dat de keuze van de methode van de statistische analyse 
op een zo objectief mogelijke manier dient te geschieden. In Hoofdstuk 1.2 wordt een 
overzicht gegeven van de tot nu toe bekende prognostische factoren bij de tumoren van 
de testis Verschillende histologische classificatie- en stagienngsmodellen worden 
beschreven en hun belang ten aanzien van de keuze van de behandeling en de prognose 
wordt benadrukt. Een combinatie van stagienngs, histologische en biochemische 
parameters maakt het mogelijk risico-groepen te definieren. Deze dienen dan als basis 
voor verder onderzoek naar prognostische factoren in deze tumoren In Hoofdstuk 1.3 
wordt een samenvatting gegeven van de belangrijkste prognostische factoren bij het 
gemetastaseerde prostaatcarcinoom. Met name de biochemische parameters zijn van 
belang voor het bepalen van de prognose en het vervolgen van de ziekte. Deze factoren 
zijn, naast de histologische en radiografische parameters, van invloed op de prognose van 
de individuele patient In Hoofdstuk 1.4. worden de prognostische factoren van het 
oppervlakkig blaascaranoom besproken. Met behulp van de klinische en pathologische 
parameters is het mogelijk de kans op een recidief carcmoom gedurende de follow-up 
te voorspellen Daar steeds meer verschillende behandelingen worden ontwikkeld, is de 
waarde van deze prognostische parameters van toenemend belang. In Hoofdstuk 1.5 
wordt een samenvatting gegeven van de prognostische factoren bij tumoren van de nier. 
Ondanks de aanwezigheid van de reeds bekende klinische, pathologische, en 
biochemische prognostische parameters, blijft het moeilijk het beloop van de ziekte exact 
te voorspellen. De prognostische factoren die van invloed zijn op de prognose worden 
in dit hoofdstuk besproken. De recente vooruitgang in het detecteren van cytogenetische 
en karyometnsche karakteristieken van de tumorcellen worden eveneens belicht. 
Het resultaat van het overzicht van de prognostische factoren zoals dat gegeven 
is in hoofdstuk I vormt het uitgangspunt voor de onderzoeken die verricht zijn in dit 
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proefschrift. Met de reeds bekende prognostische factoren als basis, zijn nieuwe 
onderzoeken geïnitieerd met als doel de prognose van een patient met een urologische 
tumor beter te kunnen definiëren. Met de resultaten hiervan kunnen adviezen verkregen 
worden voor het instellen van de juiste behandeling en het juiste follow-up schema. 
In Hoofdstuk Π onderzoeken we de waarde van de reeds bekende classificatie 
modellen van de "European Organisation for Research and Treatment of Cancer 
(EORTC)" en de Indiana (VS) groep, met betrekking tot de patiënten in het 
Radboudziekenhuis met een gemetastaseerde testis tumor. Beide modellen waren 
bruikbaar ten aanzien van het voorspellen van de overleving van deze patiënten die 
primair chemotherapeutisch werden behandeld. De grootte van de retroperitoneale 
tumor voor en na de chemotherapie bleek hierbij van additionele prognostische waarde. 
De radiografische verandering in de grootte van de retroperitoneale tumor gedurende 
de chemotherapeutische behandeling bleek een voorspellende waarde te hebben voor de 
histologie van het weefsel dat na de chemotherapie gereseceerd werd. Dientengevolge 
was deze bevinding van invloed op de prognose. Dit resultaat maakt een verdere 
individualisering van de behandeling mogelijk. 
In Hoofdstuk Ш wordt een update gegeven van prognostische factoren bij het 
gemetastaseerd prostaatcarcinoom. Deze parallel studie van een tweetal goed 
gedocumenteerde trials van hormonale behandelingen, toont aan dat met behulp van de 
parameters: algemene conditie, hemoglobine-gehalte en de hoogte van de alkalische 
fosfatase in het serum, bepaalde risicogroepen kunnen worden gevormd. Met name voor 
de, op deze wijze geformeerde groep met een slechte prognose, wordt geadviseerd 
alternatieve vormen van behandeling te onderzoeken om daarmee de prognose te 
verbeteren. 
In Hoofdstuk IV wordt de exacte waarde van de biochemische markers: alkalische 
fosfatase, prostaat zure fosfatase en het prostaat specifieke antigeen (PSA) onderzocht 
bij patiënten met een gemetastaseerd prostaatcarcinoom. Dit met name ten aanzien van 
het bepalen van de reactie van het carcinoom op de hormonale medicatie. Vooral het 
PSA gehalte bleek hierbij van waarde en kan zelfs het routinematig controleren van de 
bot-scintigrafie overbodig maken. Van deze procedure van monitoring wordt inmiddels 
gebruik gemaakt in de laatste trials. 
In Hoofdstuk V wordt een controversiële subgroep van patiënten met een 
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oppervlakkig blaascarcinoom besproken. De resultaten van de behandeling van patiënten 
met pT,G3 blaastumoren, verzameld door de urologen van het zuid-oost nederlands 
samenwerkingsverband, werden geëvalueerd, gebruikmakend van een retrospectieve 
techniek. Geen van de onderzochte parameters bleek additionele prognostische waarde 
te hebben binnen deze, door tumorstadium en gradering geselecteerde en daardoor 
homogene, groep. Vanuit deze studie kon ook geconcludeerd worden dat, na de 
transurethrale resectie van de tumor, aanvullende behandeling door middel van 
intravesicale immuno-, chemotherapie danwei radiotherapie vereist is om het recidief-
vrije-interval te verlengen. 
In Hoofdstuk VI wordt een studie verricht naar prognostische factoren bij 
patiënten met een oppervlakkig blaascarcinoom, die allen nabehandeld werden met 
intravesicale installaties van immuno- danwei chemotherapie. In deze goed 
gedocumenteerde trial bleken het aantal tumoren en de lokalisatie van de tumor in de 
blaas van prognostische waarde te zijn voor het recidief-vrije-interval. Vooral het 
voorkomen van minstens één tumor in het trigonum danwei in de achterwand van de 
blaas bleek een grotere kans te geven op een tumor recidief gedurende de follow-up. 
Geconcludeerd werd dat met name deze at risk patiënten een stringente follow-up 
behoeven. 
In Hoofdstuk VII onderzoeken we door middel van een prognostische factor-
analyse de waarde van de klinische, flowcytometrische en karyometrische karakteristieken 
bij patiënten met niertumoren. In deze heterogene groep van patiënten met alle stadia 
van het niercarcinoom, was het duidelijk dat van de klinische factoren alleen de algemene 
conditie van de patient en het gewichtsverlies van invloed waren op de prognose. Van 
de karyometrische parameters waren de karakteristieken die de heterogeniteit binnen de 
tumor uitdrukken, van belang voor de prognose van het niercelcarcinoom. Deze 
heterogeniteit zou kunnen staan voor de biologische onstabiliteit van de tumor en 
daarmede dus de overleving verslechteren. De flowcytometrische parameters vertoonden 
geen aanvullende prognostische significantie, maar dit zou veroorzaakt kunne zijn door 
het feit dat slechts één tumorsaniple werd onderzocht. De bovengenoemde heterogeniteit 
was dus niet beschikbaar voor de analyse. 
In Hoofdstuk Ш wordt een subgroep van Τ,^ Ν,,Μ,, niertumoren onderzocht ten 
aanzien van prognostische factoren. Deze studie benadrukte de waarde van de 
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karyometrische parameters; die parameters die staan voor de heterogeniteit van de tumor 
blijken van het grootste belang te zijn. In deze context geeft karyometrie informatie over 
de maligniteitspotentiaal van de tumor en kan derhalve gebruikt worden voor het 
selecteren van de juiste behandeling, bijvoorbeeld de immunothérapie. 
2. Toekomstverwachtingen 
De studies betreffende de analyse van prognostische factoren in urologische 
tumoren zullen in de toekomst een belangrijke rol blijven spelen. Naarmate het aantal 
behandelingsmogelijkheden toeneemt, zullen passende prognostische factoren nodig zijn 
voor de evaluatie. Deze prognostische stratificatie zal verder bijdragen tot een 
verbetering van de behandelingsresultaten bij patiënten met een carcinoom. Iedere fase 
III gerandomiseerde studie zal begeleid dienen te worden door een zogenaamde side-
studie van prognostische factoren. Deze goed gedocumenteerde studies geven ons de 
gelegenheid om de exacte waarde van de verschillende prognostische factoren te bepalen 
bij relatief homogene groepen van patiënten. Om het mogelijk te maken relevante 
conclusies te trekken is het nodig om een respectabel aantal patiënten te verzamelen 
binnen een korte tijdsperiode. Het is daarom van belang te adviseren grote internationale 
trials op te zetten. Dit onderstreept het belang van internationale organisaties als de 
European Organisation for Research and Treatment of Cancer (EORTC). De waarde 
van de prognostische factor analyse wordt ook verhoogd door de bestudering van een 
groot aantal patiënten, die met gebruikmaking van dezelfde inclusie en exclusie criteria 
worden verzameld, en die behandeld worden binnen een relatief korte tijdsperiode. 
Alleen op deze manier kan een nauwkeurige evaluatie van de behandeling van de 
individuele patient worden gegarandeerd. 
Om vooruitgang te boeken in de oncologische urologie is het noodzakelijk het 
onderzoek naar prognostische factoren voort te zetten. De waarde van de prognostische 
factoren moet worden gedefinieerd voor de verschillende stadia van de tumor en de 
betreffende patient. Ten aanzien van het fundamentele onderzoek, dienen de 
cytometrische, cytogenetische en moleculaire afwijkingen uitgebreid onderzocht te 
worden, zodat deze in de toekomst gebruikt kunnen worden in de routine klinische 
setting. 
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Testis tumoren 
Verder onderzoek naar het juiste tijdstip en de intensiteit van de verschillende 
behandelingsfasen van de testis tumoren zal gedaan moeten worden. Nieuwe analyses van 
prognostische factoren van grote groepen patiënten, zullen uiteindelijk beter de 
verschillende risicogroepen kunnen definiëren (Mead e.a.)· Vooral die patiënten die het 
risico lopen niet goed op de bestaande behandeling te reageren zullen moeten worden 
opgenomen in nieuwe experimentele studies. Daar deze zeer intensieve 
chemotherapeutische behandelings schema's nog steeds ernstige en in potentie letale 
bijwerkingen kunnen hebben, is het identificeren van deze patiënten met behulp van een 
prognostische factor analyse van het grootste belang. 
Vanwege de zeldzaamheid van de tumor is het van belang dat groots opgezette 
studies met medewerking van meerdere centra worden ontwikkeld, met als doel de reeds 
relatief goede prognose verder te verbeteren. Vooral meer individualisatie van de 
behandeling is gewenst; b.v. het bepalen van het juiste aantal chemotherapie kuren, 
danwei de juiste indicatiestelling tot lymfklier chirurgie. Tevens zal een betere registratie 
van de reactie van de tumor op chemotherapie een indicatie geven voor het verder 
individualiseren van de behandelingsschema's. 
Testis-tumoren worden tot nu toe vooral ingedeeld in seminoma's en non-
seminoma's, met directe consequenties voor de behandelingsmethode. In de nabije 
toekomst zullen ook andere histologische parameters van de primaire tumor (b.v. 
vaatinvasie en lymfklierinvasie) worden meegenomen in de beslissing ten aanzien van de 
behandelingsstrategieën (Sesterhenn e.a.). In een studie die zojuist gestart is, worden 
deze histologische parameters betrokken bij de evaluatie van de behandeling van deze 
patiënten. Meer experimentele studies naar cytogenische parameters zullen misschien van 
nut zijn voor het bepalen van de behandeling in de nabije toekomst. 
Prostaatcarcinoom 
Iedere patient met een prostaatcarcinoom zal op individuele basis moeten worden 
behandeld. De laatste 50 jaar zijn alle patiënten met een gemetastaseerd 
prostaatcarcinoom palliatief behandeld met hormonale medicatie, zonder dat daardoor 
de overlevingsduur evident werd verlengd. De laatste tijd worden steeds meer pogingen 
gedaan om nieuwe behandelingsmogelijkheden te ontwikkelen. Bij patiënten met een 
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prostaatcarcinoom met een geringe metastasering, wordt onderzocht of directe hormonale 
behandeling een betere prognose geeft dan alleen dan behandelen wanneer er klachten 
zijn. Aan de andere kant wordt onderzocht of patiënten die uitgebreid gemetastaseerd 
zijn beter behandeld kunnen worden door middel van het direct starten met een 
combinatie van hormonale- en chemotherapie. Een pilot-studie van deze chemo-
hormonale behandeling voor het gemetastaseerde prostaatcarcinoom vertoonde 
veelbelovende resultaten, en deze studie wordt op dit moment gecontinueerd in een grote 
fase III studie (Dawson e.a.). De selectie van patiënten voor deze studies is onder andere 
gebaseerd op de resultaten van de prognostische factor analyses uit het verleden en zijn 
goede voorbeelden voor de toekomstige behandelingsstrategie. 
Een zorgvuldige registratie van de reactie van het prostaatcarcinoom op de 
ingestelde hormonale behandeling is van groot belang gebleken. In een recent gestart 
onderzoek wordt getracht die patiënten te detecteren die minder goed reageren op de 
hormonale behandeling dan men zou verwachten op basis van de prognostische factor 
analyses. Deze patiënten zouden dan in aanmerking moeten komen voor die alternatieve 
behandelingsmethoden, die de overlevingsduur verbeteren. 
Uitgebreider experimenteel onderzoek zal in de nabije toekomst nieuwe 
prognostische parameters opleveren die de heterogeniteit binnen de tumor aangeven, met 
als consequentie een uiteenlopende reactie op de hormonale behandeling. Tot nu toe zijn 
de pogingen om een duidelijke relatie aan te tonen tussen androgeen receptor 
concentratie van de celkern en de duur van de respons op de hormonale behandeling, 
niet conclusief. Het is niet ondenkbaar dat meer resultaten zullen komen betreffende de 
detectie van nieuwe monoclonale en poh/clonale anti-androgeen receptor anti-lichamen. 
Tevens is het mogelijk dat, door middel van het nemen van prostaatbiopsieën op 
bepaalde tijdstippen gedurende de follow-up, het effect van de hormonale behandeling 
gemeten zal gaan worden (Chodak e.a.). 
Een belangrijke bevinding vanuit de tumorcel biologie, is het feit dat meer 
agressieve tumoren de neiging hebben genetisch onstabiel te zijn. De ontdekking van de 
heterogeniteit in bepaalde tumoren is recentelijk tot uitdrukking gekomen in de 
multifocaliteit van zowel diploide als non-diploïde cellen, aanwezig in dezelfde prostaat 
(Greene et al). Ook de weefsel-PSA concentraties kunnen verschillend zijn binnen 
dezelfde tumor, waardoor deze heterogeniteit in, met name de lymfkliermetastasen 
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additionele informatie zou kunnen geven ten aanzien van de prognose (Hamdy e.a.). 
Moleculaire instabiliteiten bij het prostaatcarcinoom worden gevonden bij het P53 tumor 
suppressie gen en kunnen een indicatie geven voor de kans op progressie (Effert e.a.). 
Ook een verminderde expressie van het intercellulaire adhesie molecuul E-cadherin toont 
een biologische significantie ten aanzien van de prognose van het prostaatcarcinoom door 
middel van zijn invloed op de kans op het ontwikkelen van tumor metastasen (Umbas 
e.a.). 
Blaas tumoren 
Een strikte indicatiestelling voor het starten van de juiste behandeling voor het 
oppervlakkig blaascarcinoom, blijft van belang in de nabije toekomst. Van de 
prognostische factor analyses die gedaan werden bij voorgaande behandelingen met 
adjuvante intravesicale immuno- en chemotherapie, weten we dat niet iedere tumor op 
dezelfde manier reageert op deze behandeling. Veel vooruitgang zal worden geboekt in 
de juiste selectie van patiënten voor de juiste behandelingsstrategie. Derhalve zal in de 
nieuw te ontwikkelen trials, een meer strikte indicatiestelling worden toegepast. Tevens 
zal een individualisatie van de follow-up schema's worden nagestreefd. 
In de nabije toekomst zullen de resultaten aangaande proliferatie antigenen, 
groeifactoren, proteolytische enzymen en genetische alternaties hun klinische toepassing 
bewijzen (Lipponen e.a.). Een goed voorbeeld is het p53 antigeen dat van belang blijkt 
te zijn voor de pathogeniciteit van het blaascarcinoom (Sidransky e.a.). Meer studies zijn 
in aantocht om de waarde van deze bevindingen al dan niet te bevestigen en zullen dan 
vervolgens bepalen of andere factoren zoals ploïdiciteit, verlies aan heterogeniteit en 
mutaties op andere tumor suppressor lokaties kunnen worden opgenomen in een systeem 
van moleculaire prognostische markers voor het blaascarcinoom. 
Nierceltumoren 
Ten aanzien van deze tumoren is het van belang dat verder onderzoek naar het, 
nog steeds onvoorspelbare klinische beloop van deze patiënten verricht dient te worden. 
Verwacht kan worden dat in de nabije toekomst een meer accurate voorspelling zal 
worden gedaan ten aanzien van de prognose van deze tumoren, gebruikmakend van de 
cytometrische, cytogenetische en karyometrische parameters. Een goed voorbeeld is het 
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prolifererende celkern antigeen (PCNA), dat gebruikt kan worden om patiënten te 
identificeren die kleine carcinomen hebben met een slechte prognose (Cronin e.a.). De 
reproduceerbaarheid van deze nieuwe prognostische factoren moet echter nog worden 
onderzocht. Iedere nieuw ontdekte marker moet worden onderzocht binnen verschillende 
groepen patiënten om op deze manier het belang voor de dagelijkse klinische praktijk 
te bewijzen. Een goed voorbeeld hiervan is de morfometrie van de kern. Deze zal 
gebruikt gaan worden in de routine klinische praktijk en uiteindelijk consequenties 
hebben voor de behandeling van patiënten met niercel carcinomen. Het gebruik van de 
karyometrie voor het bepalen van de prognose wordt ook aangeraden door andere 
onderzoekers (Gutierrez e.a.). Naast de reeds bestaande stagiëringssystemen zullen deze 
parameters informatie geven over het biologische gedrag en de agressiviteit van de 
tumor. De mate van heterogeniteit van de tumor zal consequenties hebben voor de 
follow-up schema's en een indicatie geven voor een eventuele adjuvante behandeling. 
Tot nu toe wordt het gebruik van adjuvante immunothérapie bij patiënten met 
een gemetastaseerd niercelcarcinoom gekarakteriseerd door een gebrek aan respons en 
het voorkomen van relatief ernstige bijwerkingen. Vooruitgang zal worden geboekt in het 
verminderen van deze bijwerkingen van vooral de immunotherapeutische middelen. 
Gebruikmakend van de resultaten van de prognostische factor analyses wordt het steeds 
duidelijker dat voor geselecteerde patiënten de reactie op deze behandelingsmethoden 
gunstiger is dan voor de gehele groep (de Mulder e.a.). Met deze twee uitgangspunten 
in het achterhoofd zullen nieuwe trials worden ontwikkeld, met als doel een betere 
respons van de niertumor op de behandeling te verkrijgen. 
In een recent gestarte trial maken we gebruik van de resultaten van de 
karyometrische analyses, uitgedrukt in de karyometrische maligniteits index. Door middel 
van deze methode kan de prognose van de individuele patient met een grotere 
nauwkeurigheid bepaald worden. In de nabije toekomst zal verdere individualisatie van 
de behandeling van patiënten met niertumoren mogelijk worden gemaakt. Dit zal dan 
uiteindelijk leiden tot een verbetering van de overleving van deze patiënten. 
Onderzoek naar prognostische factoren is een continu proces. De resultaten van 
dit proefschrift moeten derhalve aan de basis staan van toekomstig onderzoek. Iedere 
prognostische factor analyse zal nieuwe onderzoeken op zijn terrein initiëren. Essentieel 
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hierbij is het combineren van de resultaten van experimenteel en klinisch onderzoek bij 
patiënten met kanker. Het succes in het experimenteel wetenschappelijk onderzoek moet 
niet leiden tot een vermindering van het klinische onderzoek en vice versa. Alleen door 
goede samenwerking zullen de best mogelijke prognostische parameters worden 
gevonden. Uiteindelijk is dit de enige manier een verbetering te verkrijgen in de 
indicatiestelling voor de juiste behandeling teneinde de overleving te verbeteren voor 
patiënten met een urologische oncologische ziekte. 
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1. Monitoring van het gemetastaseerd testiscarcinoom gedurende de chemotherapie is 
van prognostische belang en kan leiden tot individualisatie van de behandeling, (dit 
proefschrift) 
2. Bij patiënten met een gemetastaseerd prostaatcarcinoom is het mogelijk met behulp 
van prognostische factoren risico-groepen te vormen, welke consequenties kunnen 
hebben ten aanzien van de behandeling, (dit proefschrift) 
3. Het Prostaat Specifiek Antigeen (PSA) is een adequate parameter voor de 
monitoring van behandeling van patiënten met een prostaatcarcinoom. (dit 
proefschrift) 
4. T1G3 blaascarcinomen vormen een homogene groep en dienen na transurethrale 
resectie adjuvant behandeld te worden om het recidief-vrije interval te verlengen, (dit 
proefschrift) 
5. Multipliciteit en locatie in de blaas van de met intravesicale instillaties behandelde 
oppervlakkige blaastumoren zijn van prognostische waarde voor het recidief-vrije 
interval, (dit proefschrift) 
6. Karyometrische parameters hebben bij het niercelcarcinoom additionele 
prognostische waarde, en kunnen derhalve van invloed zijn op de keuze van de 
behandeling, (dir proefschrift) 
7. Antenatale interventie bij nefro-urologische afwijkingen dient met de grootste 
terughoudendheid te worden benaderd, daarentegen kan de antenatale echoscopie 
een belangrijke bijdrage leveren aan de preventie van nierbeschadiging. 
CA.C. Hugen (Ned Tijdschr Geneeskd 1989; 133,nr 34) 
8. Patiënten met een vasectomie in de voorgeschiedenis hebben een verhoogde kans op 
het krijgen van prostaatcarcinoom (E. Giovannucci, JAMA 1993, 873,269); de reden 
hiervan dient echter aanvullend onderzocht te worden, en zou kunnen leiden tot een 
beter begrip van de etiologie van het prostaatcarcinoom. 
9. De chirurgische benadering blijft voor patiënten met een urologische tumor de enige 
kans op curatie, en moet derhalve, indien mogelijk, centraal staan bij iedere 
behandeling. 
10. Vroege detectie van een kwaadaardig gezwel kan levensreddend zíjn, derhalve dienen 
kosten nog moeite te worden bespaart om dit te bewerkstelligen. 
11. Het doen van basaal wetenschappelijk onderzoek moet niet in de plaats komen van 
het klinisch onderzoek, maar dit aanvullen om de klinische relevantie te waarborgen. 
12. Door de medicus practicus dient het woord "significant" met de nodige statistische 
argwaan te worden geïnterpreteerd. 
13. Een slecht chirurg is een chirurg die de kwaliteit van zijn operatie volledig relateert 
aan de snelheid waarmee de operatie wordt verricht. Dr. H.F. Veen, chirurg 
14. De computer is een onmisbaar werktuig geworden voor de moderne promovendus; 
het betekent echter ook dat deze de meeste secretariële ondersteuning kan, maar 
ook moet ontberen. 


